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Statement of the Problem: Respiratory Disease in Cattle 
Both human and veterinary medical fields are facing a crossroads between a growing 
bacterial resistance to antibiotics and a decreased availability of new antimicrobial 
compounds. Recent attention in our laboratory and many others has been focused upon a 
group of endogenously produced peptides with antimicrobial activity; however, the effect 
of these peptides in innate mucosal protection is poorly understood. Anionic peptide is a 
recently identified and characterized antimicrobial peptide that was isolated from ovine 
airway secretions. As cattle are of economic importance to producers and consumers 
alike, substances such as anionic peptide that may prevent pulmonary and other microbial 
infections that decrease the need for exogenous antibiotics are of potential benefit. 
Cattle producers are impacted by losses due to acute pneumonia, as well as inefficient 
weight gain of animals with chronic pneumonia. In current methods of raising, feeding, 
and housing cattle, juvenile cattle are subjected to several periods of stress. These 
include weaning, exposure to other cattle at sale bams, overcrowding in feedlots, and 
transportation. During stressful events, young cattle are at increased risk to develop 
pulmonary infections such as viral rhinitis, tracheitis, and bronchitis and secondary 
bacterial pneumonia, such as pneumonic pasteurellosis. 
Pneumonic Pasteurellosis 
Mamheimia (Pasteurella) haemolytica serotype 1 has a central role in bovine 
bacterial pneumonia. Mannheimia haemolytica inhabits the tonsil and ventral nasal 
2 
meatus of cattle (35). Under stressful conditions or following viral destruction of nasal 
and tracheal epithelium, M haemolytica proliferates and colonizes the nasopharynx (36). 
Pulmonary infection with M. haemolytica serotype 1 in ruminants often results in a severe 
fibrinopurulent bronchopneumonia. 
Methods to reduce the incidence of A/. haemolytica-d&^xHstQd disease include 
vaccination and antibiotic administration. Vaccination trials against M haemolytica have 
been partially successful. Decreased numbers of M haemolytica were recovered from 
tonsilar washes in calves vaccinated in laboratory conditions (35) and in field conditions 
(36). However, the incidence of respiratory tract disease in the field following 
vaccination was not reduced (36). Additional complications of treating bacterial 
pneumonia in cattle and sheep are the restrictions of antibiotic usage in food animals and 
regulations mandating antibiotic withdrawal times. 
Antimicrobial peptides: a potential adjunct vaccination and antibiotic therapy 
The limited effectiveness of vaccination and antibiotic therapies in prevention and 
treatment of M haemolytica pneumonia underscores the need for additional approaches 
in reducing bacterial colonization and infection. The innate immune system is becoming 
increasingly appreciated in its role in inhibiting bacterial colonization of the respiratory 
tract. The innate inunune system consists of well-known physical and physiologic 
features (i.e. mucociliary activity, lysozyme, and humidification of inspired air) and 
recently identified components such as antimicrobial peptides. Antimicrobial peptides 
serve as a part of the innate immune system, potentially reducing bacterial numbers 
nonspecifically and therefore limiting bacterial colonization (5,31,80, 120). Most 
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antimicrobial peptides are microbicidal through the formation of pores within microbial 
membranes (80). A wide range of bacteria are susceptible to antimicrobial peptides, 
including Gram-positive and Gram-negative bacteria and mycobacteria. Some 
antimicrobial peptides are upregulated in response to lipopolysaccharide (LPS) and other 
mediators of inflammation (10,90,106), while others are produced constitutively (80). 
Up-regulation of antimicrobial peptides in combination with vaccination may prove more 
effective than vaccination alone. This strategy would prime both the innate and active 
immune defenses. 
Anionic Peptide 
The antimicrobial peptide of interest to our research group is Anionic Peptide (AP), 
originally isolated from ovine bronchoalveolar lavage (BAL) fluid. Some of our 
preliminary work suggested that AP is quickly consumed during acute pulmonary 
inflanmiation. This is in contrast to some other antimicrobial peptides, which are not 
present in a steady-state quantity, but rather are upregulated in the presence of bacterial 
products (10,122). 
Because AP has potent antimicrobial activities, its contribution to the innate host 
defense system may be of particular importance in the lung. AP appears to be 
constitutively expressed and, as such, may be an essential component of the initial 
mucosal defense against colonizing and invading respiratory pathogens. Factors such as 
stress, nutritional status, immune function, and epithelial turnover rate may affect AP 
production. The lung is an important site for AP production because it has an extensive 
mucosal surface that is constantly exposed to colonizing microbes. Furthermore, AP may 
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work in concert with other endogenous antimicrobial peptides resulting in a synergistic 
effect for optimal microbial killing. 
It is our hypothesis that AP production is constitutive in epithelial cells of all ages 
(fetal to adult) of domestic ruminants (sheep and cattle). More specifically, we 
hypothesize that AP is quickly consumed in acute inflammation; this is addressed in 
Chapter 2. In Chapter 3, we tested the hypothesis that adult respiratory tissues would 
have a higher degree of AP production than neonatal or fetal tissues. We also 
hypothesize that AP production is not limited to epithelial cells of the respiratory tract, 
but that extrapulmonary production of AP occurs. In Chapter 4, we tested the hypothesis 
that AP production is decreased by subacute and chronic inflammation in the lung. 
Dissertation Organization 
This dissertation is com[)osed of a literature review (Chapter 1) and three manuscripts 
(Chapters 2-4) that have been prepared for submission for research journals. General 
Conclusions follow the last paper. Two appendices are included: Appendix A discusses 
our attempts to up-regulate Anionic Peptide in the ovine respiratory tract and Appendix B 
is a table that lists antimicrobial peptides by species. The references cited in the 
introduction, literature review, general conclusions and Appendix B are listed in the 
Bibliography following the General Conclusions section. 
Chapter 1 
The first chapter consists of a discussion of respiratory pathophysiology and 
components of innate immuniQr. The bulk of the literature reviewed concerns recently 
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described antimicrobial peptides. The literature review concludes with a brief summary 
of the properties of Anionic Peptide, the antimicrobial peptide characterized in this 
dissertation. 
Chapter 2 
Our first hypothesis was that Anionic Peptide is present in the respiratory tract of 
neonatal and young adult calves. We used immunohistochemistry to localize AP antigen 
within cells of the lung, as well as Western blot analysis to detect AP in whole lung 
tissue. The neonatal calves were inoculated with Pseudomonas aeruginosa, LPS, or 
saline, while the young adults were inoculated with Mannheimia (Pasteurella) 
haemolytica. The pattern of staining in the bovine respiratory tract was similar to that 
reported in ovine pulmonary tissues. Furthermore, there was no increase in staining 
between acutely inflamed and non-inflamed areas, which supports the notion that AP 
production is not inducible. This manuscript has been submitted to American Journal of 
Veterinary Research. 
Chapter 3 
In this manuscript, we studied the ontogeny of AP production in the respiratory 
system, and tested the hypothesis that AP is produced by epithelium outside of the adult 
bovine respiratory tract. Fetal tissues (lung, trachea, and nasal turbinate) were more 
intensely immunoreactive for AP than calves and adult cattle. There was minor variation 
between the calves and adults. AP production appears to be limited to the respiratory 
tract with a few exceptions. Extrapulmonary expression is present in the cytoplasm of 
gall bladder epithelium and root sheath epithelium of hair follicles in the skin. Nuclear 
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immunoreactivity of tubular epithelial cells predominated in the kidney, although there 
were limited, multifocal areas of cytoplasmic immunoreactivity. Uterine endometrium 
and submucosal glands were intensely immunoreactive for AP. Mucosal surfaces 
composed of stratified squamous epithelium (e.g. cheek, tongue, and esophagus) lacked 
AP-IR. Additional tissues had nuclear staining of epithelial ceils, present in small and 
large intestine, rumen, and urinary bladder epitheliimi. This manuscript is prepared for 
submission to the journal Veterinary Pathology. 
Chapter 4 
Production of AP had been assessed in cattle and sheep in acutely inflamed or non-
inflamed tissues in the previous portions of this research project. The duration of 
inoculation to euthanasia in previous studies had ranged firom six to 24 hours. There was 
no difference detected in the amount or distribution of AP expression between acutely 
inflamed tissue and healthy tissue. For this component of the dissertation, we assessed 
the distribution of AP expression in acute, subacute, and chronic lesions of Mannheimia 
(Pasteurella) haemolytica infection in the lung of ruminants. Three-month old lambs 
were inoculated by intrabronchial administration of M. haemolytica or saline, and then 
euthanatized at one day, fifteen days, or forty-five days following inoculation. There was 
mild bronchial and bronchiolar AP-IR in normal control animals, as well as in lung 
sections from the contralateral, non-inoculated, lung lobes of infected animals of all three 
groups. In the post-inoculation fifteen and forty-five day groups, there was marked AP-
IR in hyperplastic bronchiolar epithelial cells. This suggests that while AP production is 
not up regulated in response to acute inflammation, production of AP (or its parent 
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zymogen compound) occurs as a Action of epithelial hyperplasia and perhaps 
independent of lesion resolution. 
Appendix A 
For the fourth component of this project, we tested the hypothesis that accelerated 
cellular maturity and differentiation influences production of AP in ruminant lung. Our 
method of increasing cellular differentiation was to instill a soluble, non-toxic vitamin A 
derivative (retinoyl P-glucuronide, RBG) into the nasal cavity and trachea of lambs. AP 
production was assessed by immunohistochemistry. We did not detect any gross or 
histologic changes, nor changes in distribution of AP immunoreactivity, between the 
treated and non-treated groups. The inability of RBG to induce changes in epithelial 
differentiation or AP production was possibly due to inadequate dosage, limited duration 
of vitamin application, or simply that ovine tracheal epithelium of full term neonatal 
lambs is refractive to growth properties of RBG. 
Appendix B 
This appendix consists of a table listing the classes of antimicrobial peptides produced 
by humans, primates, domestic species and poultry. 
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CHAPTER ONE. LITERATURE REVIEW 
Innate Immunity in the Ruminant Respiratory Tract 
Comparative anatomy 
Variations of anatomy among species contribute to the susceptibility of a species to 
respiratory diseases. Ruminants are uniquely prone to development of pneumonia due to 
low collateral ventilation and low interdependence, resulting in reduced ability to clear 
mechanical obstructions of bronchioles. Collateral ventilation between alveoli occurs 
through pores of Kohn within alveolar septa that permit communication of the air spaces. 
The presence of airway anastamoses between bronchioles permits additional collateral 
ventilation. The ability of regions of limg to be supported structurally by adjacent regions 
(interdependence), is related to the completeness of fibrous tissue around individual lung 
lobules and the degree to which each lobule is attached to neighboring lobules by fibrous 
connective tissue. Compared to other domestic species, ruminant lungs have a low 
degree of interdependence and lack pores of Kohn, resulting in relatively less collateral 
ventilation than other species. Therefore, ruminants are less adept at clearing away 
bronchiolar obstructions (mucus, exudate) than horses, pigs, or dogs (99). This, in turn, 
leads to greater risk of bronchopneumonia and chronic scarring of bronchioles, such as 
occurs in fibrosing bronchiolitis obliterans. 
9 
Mucosal epithelium 
A basic component of innate immunity is the mucosal epithelial surface itself. The 
mucosal barrier of multiple tissues is composed of epithelial cells connected by tight 
junctions. In health, the epithelium provides a barrier that prevents migration of bacteria 
from the lumen to the submucosal tissues, such as blood vessels, lymphatics, and stromal 
interstitium. In addition, respiratory mucosal surfaces produce mucus, which bolsters the 
durability of the epithelial border by trapping particulate matter and bacteria. Factors 
with antimicrobial activity, such as lysozyme, secrctory phospholipase Ai, lactoferrin, 
and anti-leukoproteinase, have been isolated from human nasal secretions and 
bronchoalveolar lavage fluid (3, 25). 
Neutrophils in pulmonary innate immunity 
Components of the innate immune system have a vital role in reducing bacterial 
colonization and infection in the lung via non-specific mechanisms. Neutrophils and 
neutrophil granule components are perhaps the greatest repository of a variety of 
antimicrobial factors. Primary, or azurophilic neutrophil granules are lysosomes, which 
store acid hydrolases, peroxidase, lysozyme, cathepsin G, azurocidin, 
bactericidal/permeability-increasing protein, elastase, P-glucuronidase, and a-
mannosidase. Secondary, or specific granules, of the neutrophil contain lactoferrin, 
gelatinase, collagenase, NADPH oxidase, and chemoattractant receptors (127). 
Interestingly, a ioiockout model of cathepsin G deficient mice do not suffer any ill effects 
other than a transient delay in wound healing (77). Neutrophil morphology and fimction 
are normal in this model, suggesting overlapping capabilities of the granule constituents. 
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Lysozyme and lactoferrin have an unportant role in non-specific killing of bacteria. 
Lysozyme makes bacteria more vulnerable by exposing the cell membrane of bacteria 
through the hydrolysis of the muramic acid-A'-acetyl-glucosamine in the outer 
glycopeptide coat (27). Lactoferrin reduces the availability of iron in the local 
microenvironment, thus limiting the supply of a required metabolic substance for 
bacteria. The reduction of bacterial numbers through these mechanisms decreases the 
likelihood of mucosal attachment and subsequent colonization of pulmonary mucosal 
surfaces. 
Although neutrophils are recruited to eliminate pathogens and thus limit the 
desUoictive activity of potential pathogens, neutrophils can create additional damage via 
release of specific and secondary granule material. Granule constituents include 
lysosomal enzymes such as elastases, and collagenases, and products of lysosomal 
enzymes such as oxygen free radicals. Release of these contents in close proximity to 
delicate alveolar septa and bronchiolar epithelium can result in a deleterious effect in 
spite of the intended goal of antimicrobial activity. Pneumonia caused by Mannheimia 
(Pasteurella) haemolytica in cattle and sheep involves recruitment of numerous 
neutrophils that ultimately cause tissue damage. Neutrophils are recruited in large 
numbers to the sites of infection, but are highly ineffective in removing or killing the 
causative bacteria. 
Neutrophil recruitment is enhanced by secretion of a potent chemoattractant for 
neutrophils, Interleukin-8 (IL-8), a C-X-C chemokine. IL-8 is expressed by activated 
macrophages and endothelium (26), leading to infiltration of neutrophil into the local 
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environment. In ruminants with pneumonia due to M. haemolytica, numerous neutrophils 
are recruited and rapidly destroyed by leukotoxin, resulting in an inefficient inflammatory 
response associated with large areas of tissue damage and necrosis. The leukotoxin 
produced by M. haemolytica binds to Pa-integrins of leukocytes and forms pores in the 
cell membrane (24). Areas of inflamed lung in pneumonic pasteurellosis have a marked 
increase in expression of IL-8 compared to viral-induced pneumonia (21). It has been 
suggested that a reduction in neutrophil numbers in pneumonic pasteurellosis has a tissue 
protective effect. Calves depleted of neutrophils prior to experimental inoculation of M 
haemolytica have less severe clinical signs and milder lesions compared to calves with 
normal neutrophil counts (132, 116). 
Factors other than IL-8 are involved in neutrophil chemotaxis. One example is a C-X-
C chemokine, macrophage inflammatory protein-2 (MIP-2). In corneas of mice infected 
with P. aeruginosa, neutrophils are recruited by MIP-2. Perhaps more significant in 
biological terms, neutrophil numbers are reduced and lesion resolution is hastened 
following application of anti-MIP-2 antibodies (64). This suggests a role for chemokine 
regulation in the progression or resolution of suppurative lesions. Development of 
recombmant proteins has been initiated to enhance neutrophil activity, or alternatively, to 
reduce the influx of inefficient neutrophils into a lesion. As previously discussed, IL-8 is 
a potent chemoattractor and activator of neutrophils; a recombinant bovine IL-8 protein 
has been generated that acts specifically on neutrophils (22). In addition, recombinant 
bovine granulocyte-macrophage colony-stimulating-factor (GM-CSF) has a stimulatory 
effect on bovine neutrophils both in vitro and in vivo, although injection of rGM-CSF 
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results in a transient elevation of body temperature (54). These recombinant factors may 
eventually serve as pharmaceutical agents that limit excessive tissue damage caused by 
neutrophils. 
Entry of neutrophils into airway lumina occurs via two mechanisms, CDl8-dependent 
and CDl 8-independent. The CD 18-dependent pathway begins with transitory adherence 
mediated by L-selectin and P-selectin expression on the surface of neutrophils and 
endothelial cells. Upon activation, there is expression of an endothelial cell membrane 
protein, intercellular adhesion molecule-1 (ICAM-1) and neutrophil cell surface p?-
integrins. ICAM-1 and jii-integrins are expressed in response to acute inflammation, 
causing tight adhesion between neutrophils and endothelium, enabling the progression of 
neutrophil diapedesis through the vessel wall and into perivascular tissues. In most 
tissues, extravasation of neutrophils is most likely to occur in post-capillary venules. 
Radi et al. (98) demonstrated that ICAM-l is expressed not only on activated 
endothelium, but also on bronchiolar epithelium in bovine lungs. 
Animals and humans lacking the functional p-integrin subunit CD 18 have decreased 
binding to ICAM-1. This occurs in cattle (bovine leukocyte adhesion deficiency, 
BLAD)(2), golden retrievers and humans (LAD I and LAD II). Despite high numbers of 
neutrophils in systemic circulation, neutrophils are unable to cross vascular walls to foci 
of inflammation or infection; therefore, affected animals are at increased risk of disease 
caused by infection with opportunistic pathogens (2). Curiously, BLAD cattle infected 
with M haemolytica have similar numbers of neutrophils in alveolar lumina compared to 
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infected non-BLAD cattle (1). This suggests the presence of a CD18-independent 
process of neutrophil emigration specific to the lung. 
Mucosal surfaces of the respiratory tract are protected from bacterial colonization by 
ciliary activity and secretion products from epithelial cells (goblet cells) and submucosal 
glands. Present in these secretions are a variety of antimicrobial factors such as 
lysozyme, surfactant, antileukoproteinase, and secretory IgA (produced by bronchus-
associated-lymphoid-tissue). In addition, a wide range of antimicrobial peptides are 
present in the lung, produced by both myeloid and epithelial cells. 
Classes of Antimicrobial Peptides 
Antimicrobial proteins such as lactoferrin, lysozyme, phospholipase A2, and 
bactericidal/permeability increasing protein are all large molecules (arbitrarily defined as 
10 kDa or larger), (95) with antimicrobial activity. Most of these proteins are present in 
neutrophil and Paneth cell granules, as well as in respiratory tract secretions, tears and 
saliva, hi contrast, antimicrobial peptides are less than 10 kDa (38) and are produced by 
many of the same sources. The role of antimicrobial peptides in iimate mucosal 
inununity may have been previously underestimated. Antimicrobial peptides may serve 
to maintain a certain density of normal microbial flora, or remove pathogenic bacterial 
species to minimize bacterial-induced mucosal damage. Identification of antimicrobial 
peptides has occurred in a variety of species, ranging from plants (40), insects (70), 
marine invertebrates (67,68), amphibians (82), birds (15) and mammals (21, 55, 57,66, 
105,109, 117). 
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Factors that control antimicrobial peptide expression are not fiilly understood. 
Awareness of antimicrobial peptides and the factors by which they are regulated may 
allow time-dependent increases in mucosal protection during periods of stress or 
immunosuppression. Theoretically, exogenous stimulation of antimicrobial peptide 
expression could be induced in livestock prior to stresses such as shipment, or in young or 
debilitated companion animals. In comparative terms, certain populations of humans 
such as elderly patients in convalescent homes, daycare children and employees, 
handicapped individuals, patients on respirators and people with tracheostomies are at 
increased risk for respiratory infections. Respiratory infections can also have serious, 
life-threatening consequences in populations of people with decreased immune status as 
well as in animals; therefore, prevention of such infections is highly desirable. 
In the last ten to fifteen years, antimicrobial peptides have been the center of intense 
research. Generally, the peptides are classified by tertiary structure, such as beta-pleated 
sheets or alpha-helical coils, or by a common precursor. Antimicrobial peptides can be 
organized into three general classes: cysteine-stabilized peptides (defensins), 
cathelicidins, and amphipathic a-helical peptides. A table listing antimicrobial peptides 
by species is included in Appendix B. Defensins can be further subdivided into alpha (a) 
defensins, beta (P) defensins and theta (0) defensins. a-Defensins occur most typically 
within granules of granulocytes or Paneth cells of the intestine. P-Defensins are most 
fi'equently produced by epithelial cells, but some exceptions occur, such as bovine 
neutrophil P-defensins. The discovery of 0-defensins has occurred only recently. They 
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have a cyclical structure composed of two linked a-defensin transcription products. 
Cathelicidins are grouped on the basis of a common precursor, although the cathelicidins 
as a group are highly variable in structure. Finally, the a-helical peptides are arranged as 
a coil, with arrangement of specific amino acid residues on the outer surfaces. 
Cysteine-stabilized peptides (defensins) 
Defensins are small (3.5-4 kDa) cationic peptides, typically rich In arginine and 
containing six cysteines that form three disulfide bonds. The arrangement of the six-
cysteine motif is highly conserved among mammalian defensins and the linkage of the 
disulfide bonds is slightly different between a-defensins from P-defensins. A broad 
spectrum of activity has been demonstrated for defensins, including microbicidal activity 
against both Gram-positive and Gram-negative bacteria, yeasts {Candida spp.), viruses, 
and acid-fast bacteria (69, 86). Determinants of bacterial susceptibility to defensins 
include composition of the bacterial cell membrane, the metabolic phase of growth of the 
bacteria, and expression of certain virulence genes that may increase resistance to 
defensins (45,46). 
The mechanism of antimicrobial activity by defensins has not been fully elucidated. 
Initial studies using human neutrophil a-defensins and human tumor cells demonstrated a 
time lag of three to fifteen hours between addition of defensins and cytolysis (73). This 
time lag suggests that a-defensins are not directly cytolytic, but require additional 
processes of antimicrobial activity. Further studies (72) demonstrated that binding of 
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defensins to target ceil membranes is inhibited by low temperature, or the presence of 
fetal calf serum (presumably albumin). Additionally, binding of defensins to the target 
membrane alone is not sufficient for cytolysis, as internalization of defensins must also 
occur. This is demonstrated by the inhibition of cytolytic activity of membrane-bound a-
defensins in the presence of agents such as cytochlasin B or azide/2-deoxyglucose. These 
agents diminish fluidity of the cell membrane, and perhaps prevent the internalization of 
defensins. Agents that had no effect on cytolysis include vincristine and colchicine 
(inhibitors of cytoskeletal microtubules). Addition of fetal calf serum sixty minutes after 
defensin addition also had no effect on cytolysis inhibition (72). 
Defensins are capable of forming voltage-dependent ion-permeable channels in 
essentially any membrane-bound structure (tumor cell, bacteria, fungi, enveloped virus) 
(62). It has been suggested that individual defensins (cationic) are attracted to bacterial 
cell membranes by electromotive forces present between negatively charged 
glycoproteins in the lipid bilayer (62). The first contact is proposed to take place between 
arginine residues of defensins and negatively charged heads of target glycoproteins in 
lipid bilayer. Once within the lipid bilayer, defensins are thought to form multimers that 
eventually form a transmembrane pore that lyses the organism. This interaction between 
defensins (both a and P) and bacteria occurs in a tight, localized area, as the interaction of 
electromotive forces between bacteria and cationic peptides must occur within a limited 
distance (45,46). Microenvironmental factors which decrease effectiveness of defensins 
include a high salt environment (e.g. cystic fibrosis), a high local concentration of 
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divalent cations, the presence of serum (mature human neutrophil peptides bind to a-
macroglobulin) and presence of some components of complement. 
Alpha-defensins 
Classical defensins, or a-defensins, are stored in azurophil granules in neutrophils and 
in membrane-bound cytoplasmic granules in other cells such as Paneth cells. Most a-
defensins are stored preformed in granules and are packaged with anionic material (e.g. 
mucopolysaccharides). The conformational folding of immature a-defensins in granules 
is such that the negatively charged pro-piece is in apposition to the positively charged 
mature segment, thus preventing autocytoxicity to the cell (85). The six-cysteine linkage 
of a-defensins is as follows: CI to C6, C2 to C4, and C3 to C5. Human a-defensins 
(myeloid and intestinal a-defensin genes DEFAl, DEFA3, DEFA4, DEFA6, DEFA5) are 
encoded on human chromosome 8, 8p23, within a I50-kB region (74). These regions are 
within 100-150 kilobases of the P-defensin genes (75). 
Neutrophil a-defensins. In 1985, Selsted et al. purified six antimicrobial peptides from 
rabbit peritoneal neutrophils (107). These workers noted that the isolated peptides had 
selective antimicrobial activity in vitro. While regions of non-homologous amino acids 
were present among the peptides, all six peptides included six cysteine residues at exact 
positions in within each peptide. At that time, the specific linkage of cysteine residues 
through disulfide bridges was unknown. 
After a-defensins had been more fully characterized biochemically, studies continued 
to explore the microbicidal range of a-defensins. Human neutrophil a-defensins, known 
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as human neutrophil peptides (HNPl-2), are candidacidal while HNP-3 is ineffective at 
killing blastoconidia of Candida albicans (69). Additionally, HNP-1 targets the 
mycobacterial cell wall and membrane {Mycobacterium tuberculosis H37Ra), based on 
increased membrane permeability and surface changes of the cell wall (110). 
Chemotactic properties have been suggested for a-defensins. Human neutrophil a-
defensins have chemotactic properties in vitro for T-cells, but not neutrophils (23). 
Neutrophils stimulated by IL-8 release HNP-1, HNP-2 and HNP-3, as well as 
CAP37/azurocidin. Of these, HNP-1, HNP-2 and CAP37/azurocidin have strong 
chemoattractant activity of CD3+ T lymphocytes (23). In a study assessing the 
chemotactic potential for neutrophils, an increase in leukocyte influx was detected in 
mice injected intraperitoneally with HNP-1 (133). In comparison, there was no influx of 
neutrophils in leukocytopenic mice following HNP-1 administration. This suggests that 
microbicidal activity of exogenously administered HNP-1 is maximal only in the 
presence of recruited leukocytes (133). a-Defensins are not directly chemotactic for 
neutrophils, but release of a-defensins from stimulated neutrophils have been shown to 
increase IL-8 expression by cultured airway epithel ial  cel ls  (130).  The presence of  a l-
proteinase inhibitor and/or glucocorticoids block IL-8 expression by epithelial cells (130). 
In addition to a putative role in T-lymphocyte chemotaxis, studies suggest that a-
defensins initiate degranulation of mast cells. Neutrophil a-defensins induce mast cell 
degranulation and histamine release (12). Neutrophil defensins from humans, rats, guinea 
pigs, and rabbits stimulate release of histamine from mast cells independent of the 
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antigen/IgE activation pathway. Mast cells stimulated by a-defensins released histamine 
in a manner similar to degranulation due to substance P, via a G protein-dependent 
pathway. This is in contrast to IgE-dependent antigen stimulation, which requires cross-
linking of IgE molecules bound to IgE Fc receptors on the mast cell membrane. 
Blood or plasma concentrations of neutrophil a-defensins may have diagnostic value 
for distinguishing between inflammatory responses due to infection versus sterile 
inflammatory conditions. For example, systemic reaction to infection can be measured by 
assaying levels of a-defensins in plasma, blood, and body fluids. Plasma concentrations 
of HNP 1-3 are increased in humans with bacterial infections, as shown by 
radioimmunoassay and reverse phase high performance liquid chromatography (RP-
HPLC) (58). Plasma concentrations of HNPs 1-3 are increased in concert with tissue 
neutrophil mass even after the circulating number of neutrophils have decreased. The 
correlation of free, mature HNPs 1-3 bound to a2-macroglobulin, albumin or 
immunoglobulins (vs. ProHNPs, which circulate unbound) to the peripheral blood 
neutrophil count is strong. This elevation in plasma levels of HNPs 1-3 remains 
increased after resolution of systemic neutrophilia, even when large infiltrates of 
neutrophils are localized within tissues (as in Adult Respiratory Distress Syndrome). 
Therefore, these assays for free plasma HNPs 1-3 may be used as an indirect measure of 
both circulating and localized neutrophils. Increases in plasma HNP levels without 
concurrent neutrophilia might therefore help pinpoint an abscess or other source of 
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localized tissue neutrophilia that might not result in an increased circulating neutrophil 
pool. 
An additional clinical use for defensin levels can be applied to cerebrospinal fluid of 
meningitis patients. The sum of defensins and lactoferrin levels in the CSF from a patient 
with meningitis can be used to differentiate between aseptic and bacterial meningitis. 
Levels of defensin and lactoferrin levels are extremely elevated in cerebrospinal fluid 
(CSF) of children with bacterial meningitis versus those with aseptic meningitis (78). 
Human a-defensins are present in the saliva of patients with oral inflammation (87). This 
same group of researchers observed localization of anti-defensin (HNP-1) antibodies to 
Langerhans cells in oral epithelium near neoplastic lesions of oral epithelium. It has not 
been determined whether the Langerhans cells produced defensins or sequestered them 
from the environment (88). 
As is true for many neutrophil granule constituents, excessive amounts or prolonged 
exposure to a-defensins can result in tissue damage. a-Defensins isolated from the 
sputum of patients with cystic fibrosis (n=5) were present at levels higher than previously 
reported for human secretions (300 to >1600 ug/ml), even firom patients with sepsis or 
meningitis (118). The concentration of defensins present in sputum of cystic fibrosis 
patients exceeds the level reported to be cytotoxic to cultured mammalian cells. The high 
levels of a-defensin and other neutrophil products (i.e. elastase) may contribute to 
additional damage to the respiratory tract of cystic fibrosis patients. Excessive local 
levels of a-defensins may impair the antimicrobial and phagocytic activity of neutrophils. 
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This is apparently the case for neutrophils near implanted biomaterials (63). Neutrophil 
activation occurs due to contact of neutrophils with implantable biomaterial, resulting in 
release of granule contents. The presence of high concentrations of a-defensins in these 
areas decreased the phagocytic capability of neutrophils in vitro. 
In addition to the potential for tissue damage and neutrophil inactivation, neutrophil 
defensins may contribute indirectly to bacterial colonization of mucosal surfaces. Levels 
of a-defensins are also increased in the sputum of patients with chronic obstructive 
pulmonary disease (43). However, a-defensins isolated from these patients does not kill 
nonencapsulated Haemophilus influenzae. In addition, adherence and proliferation of H. 
influenzae is enhanced by the addition of HNPs 1-3 to human respiratory epithelial cell 
cultures (43). 
a-Defensins influence activity of the complement system. a-Defensins fixed in 
ELISA plates bind C Iq, thus activating the classical complement pathway (97). The 
activation of complement by Human Immunodeficiency Virus (HIV) takes place via a 
similar mechanism, through the transmembrane glycoprotein gp41. A different study 
(129) contradicts whether a-defensins activate the classical complement patliway, as this 
study shows that HNP-1 can inhibit the classical complement binding pathway via 
binding to Clq, CI, ClrandCls. 
Exogenous antimicrobial agents may assist the host response in addition to direct 
microbial killing. The antibacterial activity of the a-defensin HNP-1 has been compared 
to that of thrombin-induced platelet microbicidal protein-1 (tPMP-1), a recently described 
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cationic antimicrobial peptide of platelets. Killing of Staphylococcus aureus by both 
tPMP-l and HNP-l is enhanced by inhibition of protein synthesis and DNA synthesis 
(139). This suggests that microbicidal activity is not due to membrane disruption alone, 
but that an intracellular mechanism of killing is also required. 
The a-defensins shed in inflanunatory responses or by senescent neutrophils may 
contribute to the development of atherosclerotic plaques. Immunohistochemical stains 
demonstrated a-defensins within the intimal layer of normal vessels, and in increased 
amounts in vessels with atherosclerosis (10). Interestingly, the macrophages within 
atherosclerotic vessel walls were not immunoreactive for defensins. a-Defensins 
modulate the binding of plasminogen to fibrin yet inhibit fibrinolysis mediated by 
plasminogen activator through competitive inhibition (52). The presence of a-defensins 
in cultured endothelium and vascular smooth muscle increases the binding of lipoprotein 
(a), or Lp(a), to endothelium and smooth muscle cells (53). This suggests that uptake of 
neutrophil a-defensins by vascular endothelium might enable binding of Lp(a) to the 
vascular wall, promoting atherosclerotic plaque progression. This theory is further 
substantiated by the demonstration that a-defensins increase the binding of Lp(a) to 
purified fibronectin, and that individual a-defensins and Lp(a) molecules easily traverse 
the endothelium but lodge at the cell siuface when complexed together (11). 
While data have been presented that suggest a deleterious effect of a-defensins, there 
are data that support a tissue protective role for a-defensins. As discussed earlier, 
regulation of chemokine expression might ultimately determine progression or resolution 
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of suppurative lesions. As an example of a proinflammatory role, a-defensins stimulate 
release of IL-8 from airway epithelial cell (130). However, exposure of a-defensins to 
cultured bronchial epithelial cells causes increased release (but not increased 
transcription) of secretory leukocyte protease inhibitor (SLPI, or antiieukoprotease) (131). 
SLPI is a serine proteinase inhibitor similar to a 1-protease (al-PI, formerly al-
antitrypsin) and skin-derived antileukoproteinase (SKALP, or elafin). SLPI, al-PI and 
SKALP inhibit neutrophil elastase, among other serine proteases. a-Defensins, TNF-a, 
and IL-ip induce increased release of SLPI from cultured bronchial epithelial cells as 
well as serous cells of submucosal bronchial glands and non-ciliated bronchiolar 
epithelium (131). Conversely, release of SKALP was not affected by proinflammatory 
mediators and continued at a steady state (131). Therefore, a-defensins might serve to 
indirectly amplify an inflammatory response while inciting release of tissue protective 
protease inhibitors. 
Paneth Cell a-defensins. Paneth cells are located in the crypts of Lieberkuhn of the 
small intestine and release antimicrobial mediators from cytoplasmic granules. 
Antimicrobial molecules stored in Paneth cell granules include secretory phospholipase 
A2, lysozyme, and a-defensins. Paneth cells are more numerous in the distal small 
intestine (ileum) than in the proximal small intestine (95) and are present in very low 
levels in some species such as ruminants, swine (9), dogs, cats, and raccoons (39). 
Murine Paneth cell a-defensins. In the mouse, Paneth cell a-defensins are known as 
cryptdins. mRNA transcripts from a single mouse jejunal crypt encode six known 
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cryptdins, and eleven isoforms of cryptdin-l (92). In particular, there is great homology 
between the 17 transcripts for the propiece sequence, but mild diversity among the mature 
peptide sequences. Often the amino acid substitutions do not interfere with the charge of 
the mature cryptdin peptide, and therefore, do not affect microbicidal activity. 
Interestingly, a wide range of mouse strains (A/HeJ, AkR/J, BALB/cJ, CBA/J, CBH/HeJ, 
C57BL/10J, DBA/2J, SWR/J and Swiss Webster) lack neutrophil a-defensins (33), 
despite the wide range of a-defensins in their Paneth cells. 
Cryptdins have killing activity against Giardia lamblia (5). Cryptdin-2 and cryptdin-3 
were more potent than the a-defensins human HNP-l, rabbit NP-2, and a cathelicidin, 
bovine indolicidin against G. lamblia. Additionally, cryptdins have paracrine signaling 
activity (71). Cryptdin-2 and cryptdin-3 are capable of inducing a chloride secretory 
response &om cultured human intestinal epithelium. Chloride secretion is achieved 
through formation of anion conductive pores through the apical membranes of cultured 
enterocytes. An increase of chloride in the crypt lumen may result in "flushing" of the 
crypt, and thereby, removal of bacteria within the crypt lumen as well as reduction in 
concentration of cryptdins. 
Cryptdin activation is regulated by a metalloproteinase, another cellular product of the 
Paneth cell. This is illustrated by a mouse knockout strain, MAT -/-, in which the gene 
for the metalloproteinase matrilysin is inactivated. While transcripts for cryptdins are 
present in Paneth cells of MAT +/+ mice and MAT -/- mice, processed cryptdins are not 
detected by acid-urea polyacrylamide gel electrophoresis (AU-PAGE) from MAT -/-
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mouse intestinal extracts (134). Furthermore, there are increased amounts of unprocessed 
procryptdins from MAT -/- mice (134). While MAT -/- mice do not have increased 
incidence of enteric disease, they are less proficient at clearing bacteria following oral 
inoculation (134). 
Cryptdins have been located outside of the gastrointestinal tract, for example, in the 
skin. Cryptin-5 mRNA expression is present in skin taken from BALB/c mice (adult, 
neonatal, and embryos) as determined by RT-PCR (114). Expression of cryptdin 
transcripts is also present in cultured keratinocytes, but not in fibroblasts (114). In situ 
hybridization showed that the highest level of expression occurs in neonatal epidermis, 
while adult expression is higher in keratinocytes of the hair bulb. 
Human Paneth cell a-defensins. Only two isoforms of a-defensin are expressed by 
human Paneth cells; these are Human Defensin (HD)-5 and HD-6. In humans, Paneth 
cells are most heavily concentrated in the ileum. Jones et al. (60,61) first characterized 
genes for HD-5 and HD-6. Using Northern blotting, Southern blotting and in situ 
hybridization techniques, Jones demonstrated that both of the enteric defensins are 
expressed only in the small intestine, and specifically by Paneth cells. HD expression is 
variable during ontology from the fetus to adult (79). Expression of HD-5 in second 
trimester fetal small intestine is markedly reduced compared to adult levels of expression. 
This may be due to decreased numbers of Paneth cells in the developing small intestine as 
well as limited cellular differentiation of Paneth cells. 
Inadequate defensin production might predispose premature infants to necrotizing 
enterocolitis (79). NEC typically affects the terminal ileum of premature infants but not 
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full term neonates (79). While infectious etiologies for this syndrome are still being 
pursued, interest in the role of the undeveloped innate immune system is high. Enteric a-
defensin mRNA expression is significantly higher in tissue from NEC patients than in 
control tissues (102). It remains to be resolved whether this increased expression is in 
response to the local inflammation or a cause of NEC due to aberrant Paneth cell 
development. 
Polyclonal antibodies based on recombinant HD-5 (rHD-5) have localized HD-5 
exclusively to Paneth cell granules by immunohistochemistry and immunogold labeling 
(94). The range and optimal conditions for antibacterial activity of rHD-5 were 
determined for Listeria monocytogenes, Escherichia coli, and Salmonella typhimurium 
(95). All were susceptible to rHD-5 in a concentration dependent manner, as was 
Candida albicans. The microbicidal activity was inhibited in the presence of sodium 
chloride, and was intact within a broad range of pH variation (5.5 to 8.5). 
One challenge of studying antimicrobial peptides in humans is the difficulty in 
obtaining fresh, non-lesional material for tissue extracts. A clever solution to this 
problem was the development of a novel method of collection of HD-5 and HD-6 from 
human patients having undergone removal of the urinary bladder (96). The diseased 
urinary bladders (usually due to transitional cell carcinomas) were replaced by an ileal 
neobladder, a reconstructed 40-60 cm segment of ileum. Collection of urine from this 
ileal neobladder allowed the isolation HD-5 and HD-6, as both mature forms and variably 
processed immature forms. Phospholipase A2 and lysozyme were also present in the 
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collected urine. This model alleviates the limitation of access to human distal ileum as a 
source of HD-5 and HD-6. 
Beta-defensins 
The tertiary structure of P-defensins is similar to a-defensins, except for a slight 
variation in the disulfide linkage of cysteine residues. The linkage of p-defensin cysteine 
residues is CI to C5, C2 to C4, and C3 to C6. Genes for p-defensins differ fi-om genes 
from a-defensins in the number and arrangement of exons. P-Defensin genes are 
composed of two exons and one intron. The signal peptide is encoded by the first exon, 
and the propiece and mature peptide sequences are encoded on the second exon (30, 75, 
76). In mammals that have both a- and p-defensins (mice, humans), the genes for these 
peptides are located within close approximation to each other on one chromosome (75, 
90). While most p-defensins are produced by epithelial cells, there are a few exceptions, 
such as bovine neutrophil P-defensins and avian heterophil defensins. The spectrum of 
antimicrobial activity is similar to that of a-defensins. One major difference of P-
defensins is that unlike the constitutively produced a-defensins, some P-defensins are 
only produced in response to inflammation. Originally isolated from bovine neutrophil 
granules, the "P" designation was first given to these peptides by Selsted et al., 1993 
(108), to distinguish them from the classical defensins. 
Bovine B-Defensins. p-Defensins were described first in the bovine. Genes for 
thirteen putative neutrophil P-defensins, Bovine Neutrophil p-defensins (BNBD) 1-13 are 
present m the bovine genome (108). P-Defensins have been isolated from epithelial 
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tissues of the respiratory tract and oral mucosa. The first epithelial P-defensin, tracheal 
antimicrobial peptide (TAP) was detected in bovine tracheal epithelium (29, 30). mRNA 
transcripts for a second epithelial defensin, lingual antimicrobial peptide (LAP) are 
present in bovine glossal epithelial cells (105). Production of both peptides (TAP and 
LAP) is inducible in response to inflammation or inflammatory mediators such as LPS or 
TNF-a (31, 100, 120). There are binding sites for NF-icB and NF IL-6 in the 5' flanking 
region of the TAP gene (32). Therefore, similar to human P-defensin-2 (to be discussed 
later), induction of TAP by LPS is controlled at the level of transcription (32). Genes for 
P-defensins BNBD-4 and BNBD-5 are present in bovine alveolar macrophages (101), but 
are constitutively produced rather than induced by inflammatory mediators. Enteric P-
defensins (EBD) are present in bovine small intestine and colon, and are expressed in 
response to Cryptosporidium parvum (122). 
Human B-defensins. The study of P-defensins in humans is driven, in part, by the need 
to better understand the pathogenic mechanisms of cystic fibrosis. The pulmonary lesions 
of cystic fibrosis share features with chronic bronchopneumonia, except that this chronic 
lesion occurs in very young individuals with cystic fibrosis. Large numbers of 
neutrophils are present in these lesions; however, the presence of neutrophils does not 
lead to resolution of the lesion. Another curious aspect of cystic fibrosis is that the 
bacteria isolated from such cases are typically Pseudomonas aeruginosa, Burkholderia 
cepacia, and other organisms that are not traditionally recognized as primary pathogens. 
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One theory for the increased susceptibility of cystic fibrosis patients to infection with 
P. aeruginosa and B. cepacia has been proposed by Pier et al. (93, 142). hi this theory, 
bacteria are removed from the bronchiolar environment by epithelial cell uptake and 
subsequent sloughing of individual epithelial cells that contain bacteria. According to 
Pier's hypothesis, bronchiolar epithelium with the mutated cystic fibrosis transmembrane 
conductance regulator (CFTR) protein lacks the ability to attach to and phagocytize 
bacteria; thus, luminal bacteria are not taken up from the lumen at a normal rate. 
A competing theory, one that emphasizes the potential importance of defensins in 
innate immunity, is that the putative loss of P-defensin activity in the bronchioles of 
cystic fibrosis patients results in chronic, opportunist-induced bronchopneumonia. The 
microbicidal activity of |3-defensins, and perhaps all antimicrobial peptides, is highly 
dependent on the microenvironment. This is perhaps best illustrated by the syndrome of 
cystic fibrosis, in which an altered membrane chloride channel releases excessive 
amounts of chloride from the bronchiolar submucosal cells. Abnormal chloride channels, 
or CFTR, present in cystic fibrosis patients result in a higher salinity of airway surface 
fluid (117). HBD-1 is inactivated by airway surface fluid of cystic fibrosis patients, and 
the fluid has reduced microbicidal activity compared to normal patients (42). Expression 
of the HBD-l gene is present in both normal and CP patient respiratory epithelium and is 
inactivated via antisense oligonucleotides, resulting in loss of antimicrobial activity (42). 
Human p-defensin-1 (HBD-l) was first isolated from hemofiltrate of renal failure 
patients in 1995 (13). While a-defensins are present in bone marrow, peripheral blood 
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leukocytes, spleen, thymus, and small intestine, P-defensin (HBD-1) is present in 
pancreas and kidney in high levels, and lower levels in other tissues (salivary gland, 
trachea, prostate) (146). Transcripts of HBD-1 are also present in cultured tracheal 
epithelium (146). The gene for HBD-1 (HDEFBl) is within a cluster of genes for 
myeloid and intestinal a-defensins on the short arm of human chromosome 8 (74). 
Concurrent with the finding of an epithelial p-defensin in cattle (42), McCray and co­
workers reported the expression of a p-defensin in human airway epithelium (83). 
Comparison of amino acid sequences between tliis novel human P-defensin and the 
bovine P-defensins TAP and LAP establishes homology of the six-cysteine motif in the 
bovine and human peptides. Constitutive production of HBD-l is present in kidney, 
female reproductive tract, voided urine (128), conjunctiva (51) lung (83, 115), small and 
large intestinal epithelium (91), tympanic membrane and auditory canal epithelium (14), 
and oral cavity (including gingiva, parotid gland, buccal mucosa and tongue) (81). 
Some controversy exists concerning the isolation of HBD-1 from BAL fluid. Some 
attempts to recover HBD-1 from BAL fluid have been unsuccessfiil (104). Instead, 
human neutrophil a-defensins, HNP-1, HNP-2, and HNP-3 have been recovered from 
BAL fluid. These peptides, along with lysozyme, were suggested to be the major 
antimicrobial factors in human BAL fluid. This contradicts the findings of other papers, 
in which HBD-1 was recovered from BAL fluid of normal and diseased patients (115). A 
second human p-defensin, HBD-2, has been recovered from BAL fluid only in CF 
patients (115). This difference in findings might be due to difference in technique, or 
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difference in concentrations of tlie different peptide. Epithelial defensins are known to be 
active in high concentration in local microenvironments, but may not be highly 
concentrated enough to detect in whole BAL fluid. 
A second (J-defensin was first identified in human psoriatic skin (48) and has a unique 
feature of inducible expression. This peptide, HBD-2, is bactericidal to Gram-negative 
bacteria and yeast {Candida albicans), and weakly effective against Gram-positive 
bacteria (48). While Pseiidomonas aeruginosa is susceptible to HBD-2, Burkholderia 
cepacia is resistant (6). Production of HBD-2 appears to require proinflammatory 
stimuli, and it has been located in inflamed skin (76, 106), inflamed mammary gland (76), 
conjunctiva (51), inflamed colonic epithelium (91), lung (106, 115) and bronchoalveolar 
lavage fluid from patients with cystic fibrosis (115). Transcription of HBD-2 is increased 
in response to TNF-a and bacteria (48). Human fetal colonic xenografts and human 
colonic epithelial cell lines HT-29 and Caco-2 can be induced to produce HBD-2 in the 
presence of IL-la or bacteria (91). HBD-2 is constitutively expressed in foreskin 
keratinocytes, lung, trachea, and uterus (48). Consensus binding sequences for NF-kB 
are present on the 5' flanking region of the genomic sequence of HBD-2, but not for 
HBD-1 (76, 106). IL-la, IL-ip and LPS also up-regulate HBD-2 (81, 91). The HBD-2 
gene is located on human chromosome 8p, is more centeromeric compared to HNP-1 and 
HBD-1, and is 2kb including the typical p-defensin motif of two exons and one intron 
(76). 
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Defensins may function beyond simple antibacterial protection. HBD-2 and magainin-
2 amide caused death of 2-cell embryos as well as bacteria (103). The concentration that 
kills embryos is higher than normal antimicrobial MICs (50ug/ml for HBD-2,250ug/ml 
for magainin-2). These results suggest that antimicrobial peptides may be a cause of 
some cases of idiopathic infertility. 
As is true for a-defensins, P-defensins may function as chemotactic factors in 
additional to antimicrobial activity. As discussed previously, a-defensins HNP-1, HNP-
2, and CAP37/Azurocidin have chemoattractant properties for T-lymphocytes (23). P-
Defensins compete with liver and activation-regulated chemokine (LARC, or MIP-3a) 
for binding to chemokine receptor-6 (CCR6), a receptor on epithelial dendritic cells 
(140). HBD-2 may serve as a direct antimicrobial weapon and to recruit T-lymphocytes 
to the site of microbial invasion, as gene expression of HBD-2 in skin is upregulated in 
the presence of inflammation. 
Murine B-defensins. A murine gene homologous to HBD-1 is present in the mouse 
genome (55). This peptide, mouse |3-defensin-l (MBD-I), is expressed in a similar 
pattern to HBD-1 (high levels in kidney, lower levels in Gl, respiratory tracts). The 
MBD-1 gene (known as Dejbl, 89) is located on mouse chromosome 8, near the region of 
a-defensins genes. Transcripts of MBD-1 mRNA are present in kidney, liver, and female 
reproductive tract (7). Additionally, MBD-l transcripts are present in epithelium of large 
airways and, to a lesser degree, m smaller airways. Furthermore, MBD-1 is inactivated 
by either a high salt environment, or an acidic pH. MBD-1 is antibacterial against both 
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Gram-positive and Gram-negative bacteria, but lacks antimicrobial activity against B. 
cepacia (89). MBD-l is not upregulated in response to LPS (89). 
A gene for a second mouse P-defensin, Dejb2, was identified in the murine genome 
(90). Comparable to HBD-2, this gene is not expressed without an inflammatory 
stimulus. There are no reports of biochemical or antimicrobial properties of mouse P-
defensin-2. 
A novel mouse P-defensin (MBD-3) has been cloned (8). MBD-3 transcripts are 
present at low levels in the lung, but are greatly increased in lung, liver and small bowel 
following administration of Pseudomonas aeruginosa PAOl into the lung (8). Similar to 
HBD-2 and Dejb2, expression of MBD-3 is increased in inflamed tissues. MBD-3 is 
microbicidal against Gram-positive and Gram-negative bacteria in a salt dependent 
maimer. The gene for MBD-3 Is located on mouse chromosome 8, near the cluster of 
genes for cryptdin a-defensins (8). 
A mouse model of cystic fibrosis has been developed to study the role of p-defensins 
(84). Attempts were made to recreate the high salinity microenvironment of small 
airways in CF patients by disrupting the CFTR gene in mice (AF508). However, AF508 
homozygous and heterozygous mouse strains do not develop lesions of 
bronchopneumonia without repeated administrations of bacteria. One explanation for the 
inability to reproduce chronic bronchopneumonia in AF508 homozygous mice is that this 
particular mutation of the CFTR gene did not result in a sufficient increase of chloride in 
small airways. Therefore, although MBD-l is salt-sensitive, the concentration of salt in 
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the airway surface fluid of these mice is not high enough to abolish microbicidal activity 
(84). 
Recently, two P-defensins have been characterized in rats (RBD-1 and RBD-2) (59). 
There is homology between HBD-I, MBD-1, and RBD-1, while bovine TAP, RBD-2, 
and HBD-2 share homology. The rat P-defensin genes are located on rat chromosome 16, 
near genes for a-defensins. 
Ovine B-Defensins. Ovine genes encoding antimicrobial peptides were identified by 
cDNA isolation, PGR, and southern blot analysis (57). Two p-defensins and eight 
cathelicidins (to be discussed later) were characterized. The genes for the two sheep p-
defensins, SBD-l and SBD-2 are located on sheep chromosome 26. This is an interesting 
contrast to the bovine in which over thirteen potential P-defensins are encoded in the 
genome. Unlike the bovine, myeloid p-defensins have yet to be discovered in sheep. 
SBD-I expression predominates in the gastrointestinal tract, except in the distal ileum 
where SBD-2 is expressed in higher quantity (56). Transcripts for SBD-l are also present 
in the trachea and lung. 
Porcine B-defensins. Porcine p defensin-1 (PBD-l) has been identified in the 
respiratory tract, gastrointestinal tract, as well as in numerous other tissues (thymus, 
spleen, lymph node, brain, liver, kidney, urinary bladder, testis, skin, neutrophils, 
umbilical cord, bone marrow and alveolar macrophages) of the pig (144). PBD-l is 
present in high concentrations of the comified epithelium of the dorsal tongue, especially 
in the tips of the filiform papillae (113). The p5D-/gene is located on porcine 
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chromosome 15ql4-ql5.1 and is expressed constitutively in inflamed and non-inflamed 
tissues (145). 
Avian B-defensins. As avian heterophils lack myeoloperoxidase, the basis for 
heterophil bactericidal activity is poorly understood. Avian heterophils express (3-
defensins and the presence of p-defensins within heterophil granules may alleviate the 
need for free radical production. Five avian P-defensins have been characterized. This 
includes amino acid sequences for five chicken and turkey heterophil P-defensins (34). 
Partial amino acid sequences for CHP-1 and CHP-2 (now known as Gallinacins-1 and -2, 
or Gal-1 and Gal-2), as well as three turkey heterophil peptides, THP-l, THP-2, and 
THP-3. Gal-1, Gal-2, and THP-l were determined to share homology in arrangement of 
cysteines with the bovine P-defensins TAP and LAP. The conservation of amino acid 
sequences between avian and mammalian defensins prompted speculation that P-
defensins flmctioned in innate immunity before the divergence of mammalian and avian 
predecessors (49). The cDNA sequences of the gallinacins and turkey heterophil 
peptides-1 and -2 indicate that peptides lack the long, negatively charged propiece 
(putative charge-neutralization function) present in mammalian myeloid a-defensins (15). 
In contrast to the first peptide sequence proposed (49), Brockus et al. (15) reported that 
Gal-1 and THP-l share a cysteine backbone structure similar to bovine P-defensins TAP 
and LAP; sequences for Gal-2 and THP-2 have a slight shift of the first cysteine residue. 
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Plant defensins 
Plant defensins are larger (45-54 amino acid residues) and distinctly different in 
structure than those described for animals. The cysteine backbone characteristic of 
defensin peptides is composed of eight cysteines rather than six, and they are arranged 
into a different linkage of disulfide bonds than a or P defensins (40). Plant defensins are 
growth inhibitors of fimgi (40, 123, 124). Unlike insect and mammalian defensins, plant 
defensins do not form ion-permeable pores in artificial membranes (124). Plant defensins 
are divided into two broad groups (A and B), with four subfamilies of group A, based on 
structure and spectrum of antimicrobial activity. Subfamily A2 includes Dm-AMP-1, 
AhAMP-1, and Ct-AMP-l, which are non-morphogenic defensins (unlike other plant 
defensins, this group does not cause structural changes in fungi) that induce membrane 
potential changes in fungi (reviewed by Thevissen et al., 124). The plant defensin 
DmAMPl, produced by seeds of Dahlia merckii, causes permeabilization only by specific 
membrane binding sites, as demonstrated by receptor-mediated uptake of fluorescent dye 
(123). Additional studies show that DmAMPl binds to filamentous and unicellular fungi 
in an irreversible, specific, and saturable process (124). Most plant defensins are 
expressed in a tissue specific maimer, with placement of defensin groups at sites most 
appropriate for the pathogens most likely to be encountered (40). Many other types of 
antimicrobial peptides are present in plants, such as thionins, lipid transfer proteins, 




Most recently, a new class of defensins previously described in plants has been 
identified in neutrophils of rhesus macaques. This novel defensin appears to be the 
product of two a-defensin-like peptides (121). This new peptide, a 0-defensin, is an 18-
residue macrocyclic, tridisulfide peptide that has greatest antimicrobial activity as a cyclic 
structure rather than the acyclic analog. The rhesus theta-defensins (RTD-1) are thought 
to be more stable in the cyclic form due to protection from exopeptidases and proteases 
present in inflammatory exudate. 
While primates produce this class of peptides de novo, rabbit a-defensins have been 
used to produce a similar structure through laboratory manipulation. Circularized analogs 
referred to as "P-tile" peptides were generated by joining two rabbit neutrophil peptides 
by thia zip cyclization (141). These peptides are dramatically more resistant to high salt 
conditions compared to the rabbit a-defensins used to make the cyclical structure. This 
cyclical structure, and process of circularization of a-defensins, shows promise for 
pharmaceutical manipulation. 
Saposins 
Antimicrobial peptide expression is not limited to epithelium or neutrophils. Granules 
of cytolytic T lymphocytes and natural killer (NK) cells of humans contain granulysin, a 
member of a class of cysteine-stabilized peptides known as saposins (65,119). These 
proteins interact with lipids; granulysin has distinct antimicrobial activity against 
Mycobacterium tuberculosis (119), as well as Gram-positive, Gram-negative, and fungal 
38 
organisms (65). Granulysin has a five-cysteine, 1-tyrosine motif and hydrophobic residues 
in conserved positions relative to other saponin peptides (65). In order for granulysin 
molecules to kill intracellular mycobacterial organisms, the pore-forming activity of 
molecules such as perforin is required (119). The combination of perforin (another 
component of NK cell granules) and granulysin allows entry of the antimicrobial peptide 
into phagolysosomes (119). 
Cathelicidins 
Cathelicidins are a widely variable group of antimicrobial peptides that are most 
commonly packaged in granules of myeloid cells. While the mature product of 
cathelicidins are highly variable in size, amino acid content, and structure, the pro-region 
of the immature protein products are highly homologous. Furthermore, most 
cathelicidins require elastase activation and share a conserved elastase binding site. A 
common theme among the cathelicidins is a four exon gene structure, in which the fourth 
exon codes for the mature, variable peptide while the first three code for the proregion 
and activation site (74, 143). Expression of cathelicidin mRNA is only detected in 
immature neutrophils (143) and inflamed human keratinocytes (37). The proregion, 
cathelin, of this group of antimicrobial peptides is thought to fianction as a protease 
inhibitor. 
Cathelicidins have been studied in several species, including humans (4,29,44, 126), 
rabbits (CAP18), pigs (66, 112, 138), sheep and goats (109), and cattle (136). The human 
cathelicidin LL-37 is unique in that it is the only one produced in neutrophils and 
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epithelium, the only one upregulated in response to inflammation and the only human 
cathelicidin (37). An interesting inverse correlation exists in some species, in that those 
species with few myeloid defensins appear to have a broader range of myeloid 
cathelicidins than do those species with numerous myeloid defensins. For example, 
myeloid defensins have not been identified in porcine granulocytes, yet at least nine 
porcine cathelicidins have been identified in porcine neutrophil granules. These are PR-
39 (4, 111, 138), Protegrins 1-5 (112,138), Tritrpticin (66), Prophenin-l (50), and 
PMAP-37 (125). Similarly, ovine neutrophils are apparently devoid of either a- or P-
defensins, but evidence for the potential of eight different ovine cathelicidins is present in 
the ovine genome (57). Huttner et al. (57) localized the genes for OaDodeA, OaDodeB, 
OaMAP-34, OaBac5, OaBac7.5, OaBacl 1, and OaBac6 to sheep chromosome 19. 
Cathelicidins were purified from sheep and goat neutrophils (OaBacSa in sheep, and 
ChBac5 in goats) (109). Bac5 from both goats and sheep is a proline-rich cathelicidin 
that is active against Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis, and 
Listeria monocytogenes under both high and low salt conditions, but the spectrum of 
antimicrobial activity is limited to Gram-positive bacteria and yeast in low salt 
conditions. Bactenecin, also known as cyclic dodecapeptide or Bac5, was originally 
isolated from bovine neutrophils. The single disulfide bond within the cyclical 
bactenecin was disrupted and the antimicrobial activity of the resultant linear peptide was 
compared to the natural, cyclical peptide (136). The cyclical peptide was only active 
against Gram-negative organisms, while the linear peptide was active only against Gram-
positive species. Bactenecin has been targeted for pharmaceutical manipulation due to 
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the small size and single disulfide bond. Addition of a tryptophan within the P-hairpin 
loop and an increase in the positive charge at both ends of the peptide results in increased 
antimicrobial activity and spectrum (137). One other bovine cathelicidin, BMAP-34, was 
identified in neutrophils (41). BMAP-34 has high homology to the ovine OaMAP-34, 
and is similar to porcine PMAP-37 and mouse CRAMP, all of which are a-helical 
peptides. 
The cathelicidin family is subdivided by structure and amino acid composition. The a-
helical cathelicidins include porcine PMAP-37, bovine BMAP-34, ovine OaMAP-34, 
mouse CRAMP, rabbit CAP 18, human LL-37 (hCAP-18). Proline- and arginine-rich 
cathelicidins include PR-39 in pigs, bactenecin (Bac 5, Bac 7, Dodecapeptide) in cattle, 
sheep, goats, and prophenin-1 in pigs. The cyclic dodecapeptide, bactenecin, is also listed 
as a cysteine-rich cathelicidin or loop molecule in some articles due to the presence of the 
hairpin loop. The fourth category of cathelicidins is the tryptophan-rich peptides, such as 
porcine indolicidin, tritrpticin, and PMAP-23. 
The mechanism of bacterial killing of these shorter, non-defensin antimicrobial 
peptides is slightly different from what has been proposed for the cysteine-rich defensins. 
A model proposed by Matsuzaki et al. (82) and Wu et al. (135) states that some 
antimicrobial peptides bind to the outer leaflet of cell membranes, then flip inwards, such 
that membrane lipids are carried into the cytosol causing brief disruptions in permeability. 
These researchers (both Wu and Matsuzaki) used a-helical peptides (discussed below), as 
well as indolicidin, bactenecin, gramicidin S, and several synthetic derivatives. 
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Indolicidin is unique in its antimicrobial mechanism, as it appears to have an anti-
endotoxic effect by means of displacing divalent cations from lipopolysaccharide on the 
surface of Gram-negative bacterial, leading to distortion of the outer-membrane structure 
(45). 
Amphipathic a-helical peptides 
The a-helical peptides are produced by a variety of nonmammalian and invertebrate 
species. These include magainins, from frogs; cecropin, from moths {Hyalophora 
cecropin); melittin, from bees; clavanins, from tunicates. In addition, one of the 
previously discussed cathelicidin groups (e.g. human LL-37, porcine PMAP-37, and 
bovine BMAP-34) is characterized by the a-helical structure. Magainins were originally 
isolated from the granular glands of frog skin (African clawed frogs, Xenopus laevis). 
Synthetic magainins are currently in clinical trials for pharmaceutical use (47). 
Clavanins are histidine-rich a-helical peptides isolated from hemocytes of the tunicate 
Styela clava (68). Unlike other cationic a-helical peptides, the cationic charge of 
clavanins results largely from the histidine residues rather than lysine or arginine residues. 
This difference in amino acid composition is thought to enable the peptide to function at 
low pH conditions (5.0 to 5.5) as demonstrated by Lee et al (67). Clavanins also maintain 
antimicrobial activity in high salt conditions (67). 
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Conclusion 
Because antimicrobial peptides have been a part of the innate immune system 
throughout evolution, it is clear that the presence of antimicrobial peptides alone does not 
prevent bacterial colonization and infection. These peptides are one component of innate 
mucosal immunity, along with neutrophil activity (e.g. phagocytosis, oxidative burst), 
nonspecific phagocytosis by macrophages, epithelial barriers and secretions. However, in 
absence of functional antimicrobial peptides, mucosal surfaces are potentially at increased 
risk of colonization, as in the example of bronchopneumonia of cystic fibrosis. The role 
of antimicrobial peptides may exceed that of nonspecific killing of bacteria; recent 
evidence suggests chemoattractant properties of several antimicrobial peptides for T-
lymphocytes, mast cells, and indirect chemotaxis of a-defensins for neutrophils via IL-8 
expression. Pharmaceutical production of amphipathic a-helical peptides and novel 
cyclical a-defensins analogs (or theta-defensins) is currently underway with promising 
early results. These engineered antimicrobial peptides may have beneficial effects either 
alone, or as a synergistic effect with traditional antimicrobial therapies and drugs. 
Anionic Peptide 
The discovery of anionic peptide (AP) and its antimicrobial activity occurred by 
observation of antimicrobial activity of pulmonary surfactant in the presence of normal 
serum (16). Several strains of Pasteurella haemolytica, as well as Escherichia coli, and 
Klebsiella pneumoniae strains were susceptible to the pulmonary surfactant while P. 
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multocida, Serratia marcescens, and Pseudomonas aeruginosa were resistant. 
Complement, antibodies, and lysozyme were subsequently eliminated as possible causes 
of the antimicrobial activity. A group of peptides originally named surfactant-associated 
anionic peptide was eventually isolated from ovine pulmonary surfactant (17). Brogden 
et al. extracted these peptides from pulmonary surfactant by of high-speed centrifugation, 
high performance liquid chromatography (HPLC), and acetonitrile elution. This resulted 
in the isolation of three bactericidal fractions, later sequenced as H-GDDDDDD-OH, H-
DDDDDDD-OH, and H-GADDDDD-OH. Bactericidal activity of these peptides is 
enhanced by the presence of ZnCb, and is reduced in the presence of phosphates. These 
peptides are small (722-824 Da) and homopolymeric (17), and it has been suggested that 
they might be the products of enzymatic cleavage from a larger, yet unknown, peptide 
(18). This concept was explored further when Brogden compared antimicrobial activity 
of two other zymogen propiece fragments to AP (referred to as respiratory-associated 
anionic peptide at that time) (18). Susceptibility of Gram-negative and Gram-positive 
bacteria to trypsinogen activation peptide and frog hormone PYL activation peptide to 
were compared to bactericidal activity of AP. Bactericidal activity was present in all 
three peptides and Gram-negative bacteria were more susceptible than Gram-positive 
bacteria. Thus, propiece fragments of zymogens were shown to function not only to 
neutralize the charge of its cationic mature peptide, but also to have low level, innate 
bactericidal activity. 
Brogden et al. have determined that AP is produced by epithelial cells of the lung of 
sheep and humans (19, 20). Anionic peptide (AP) production has not been previously 
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determined in cattle. AP production during pneumonia has not been assessed in any 
species but has recently been shown to be decreased in alveolar epithelium and BAL fluid 
from lungs of humans with cystic fibrosis (20). 
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CHAPTER TWO. DISTRIBUTION OF SMALL ANIONIC ANTIMICROBIAL 
PEPTIDES IN PNEUMONIC AND NON-PNEUMONIC LUNGS OF CATTLE 
A paper submitted to American Journal of Veterinary Research^ ' 
Amanda J. Fales-Williams^, Kim A. Brogden'*, Elise Huffman, 
Jack M. Gallup, Mark R. Ackermann^ 
Abstract 
Objective. Anionic peptides (AP) are small antimicrobial peptides originally purified 
from ovine bronchoalveolar lavage (BAL) fluid and lung. The objective is to establish 
the presence of AP in normal and pneumonic lungs of cattle. 
Animals. Six healthy neonatal Holstein calves and four healthy young adult calves. 
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Procedure. The calves were inoculated with inflammatory stimuli {Mamheimia 
haemolytica, Pseiidomonas aeruginosa, or LPS of both organsims), or pyrogen-ftee 
saline by fiberoptic bronchoscopy. Lung tissue was collected for electrophoresis, western 
blot analysis and immunohistochemistry. 
Results. AP was detected by western blots and immunohistochemistry in normal and 
pneumonic lung tissue from neonatal calves and young adult cattle. AP was also detected 
in lung and BAL fluid from adult cattle. Mouse anti-AP IgG (IG9-IC2) reacted with four 
bands (approximate weights): 28-30 kDa (strongest signal), 31 kDa, variable band in 
calves at 45 kDa and at 35-38 kDa in an adult (cow), and an inconsistent 64 kDa band. 
These band sizes are consistent with those in western blots of ovine lung and trachea and 
most likely represent the proposed intact zymogen prior to post-translational cleavage. 
Immunohistochemistry of cattle lung tissue, both normal and infected, had a pattern of 
immunoreactivity similar to sheep lung tissue. 
Conclusions. In contrast to inducible antimicrobial peptides, AP production was not 
increased by a variety of proinflammatory substances, and greater AP-IR in non-inflamed 
lung compared to inflamed lung suggests stored AP may be constitutively produced and 
rapidly expended in acute inflammation. This work demonstrates that AP is present in 
lung and BAL fluid of cattle in a distribution similar to sheep and that AP production is 
not enhanced by infection or acute inflammation. 
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Introduction 
Throughout gestation and after birth, the respiratory tract is constantly exposed to a 
variety of substances such as fluids (fetal fluids or water in humidified air), particulate 
matter, gases, and microbes. After birth, the respiratory mucosa is in contact with a 
steady flow of environmental air that is essential for uptake of oxygen and release of 
carbon dioxide across the alveolar septa. Because of this close association of respiratory 
mucosa to envirormiental substances, irmate defense mechanisms exist to protect the host 
against microbial colonization and infection. These mechanisms include the mucociliary 
apparatus, surfactant and surfactant proteins, alveolar macrophages, and an intact 
epithelium. 
Recently, several classes of antimicrobial proteins and peptides (AMP) produced by 
respiratory mucosal cells have become increasingly appreciated in their contribution to 
innate defense against microbial pathogens (1). These include peroxidase, lactoferrin, 
lysozyme, bacterial permeability-inducing protein-1, serpocidins, phospholipase A2, 
secretory leukoprotease inhibitor, defensins and cathelicidins. Expression of some of 
these, notably the human cathelicidin LL37 and p-defensins in man (hBD-2) and cattle 
(tracheal antimicrobial peptide [TAP] and lingual antimicrobial peptide [LAP]), (2,3,4) 
are induced by inflarrmiation. Brogden et al. have determined that a class of peptides 
with anionic properties also has antimicrobial activity and is produced by epithelial cells 
of the lung of sheep and humans (5,6). Anionic peptide (AP) production has not been 
previously determined in cattle. AP production during pneumonia has not been assessed 
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in any species but has recently been shown to be decreased in alveolar epithelium and 
BAL fluid from lungs of humans with cystic fibrosis (7). 
AP is distinct from many AMPs for the following reasons: it is small, it is anionic due 
to homopolymeric regions of aspartate, it requires zinc as a cofactor for bactericidal 
activity, and it is present in pulmonary surfactant (5,8). It has been suggested that A? 
may be a product of post-transitional cleavage of a larger peptide, such as a zymogen (6). 
The identity of the mature protein product from which AP is cleaved is not yet known. 
Similar to other AMPs, AP is bactericidal against Gram-positive and Gram-negative 
organisms. Efficacy of AP microbial killing is inversely proportionate to the number of 
aspartate residues in the peptide (5,8). The mechanism of bacterial killing has not been 
fully elucidated but is thought to involve the bacterial uptake of AP and zinc. AP 
bactericidal activity is inhibited in the presence of phosphates or EDTA (5). Recent work 
indicates the presence of AP-containing proteins in trachea, nasal epithelium, liver and 
small intestine of the sheep (9,10). Degenerate oligonucleotides were synthesized to 
identify precursor genes for AP in sheep genomic DNA; these probes hybridized with 
larger sequences, further indicating the likelihood that AP is a precursor portion of a 
zymogen (9). 
The purpose of this study was to determine if AP is present in bovine lung and if 
present, identify cell types that produce AP. We assessed the presence of AP in the lung 
of neonatal and young adult cattle. We also determined the cell types involved in AP 
production in the lung of cattle and compared the degree of expression of normal lungs to 
lungs inoculated with two Gram-negative bacterial organisms, the common Gram-
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negative bacterial pathogen of ruminants, Mannheimia (Pasteurella) haemolytica, and 
Pseudomonas aeruginosa, an opportunistic pathogen. 
Material and Methods 
Animals and tissues. Six healthy male Holstein calves were deprived of colostrum 
and brought to the Iowa State University Laboratory Animal Resources facility within 24 
hours of birth. Two lung lobes of each calf were inoculated with 5 ml of live or heat 
killed bacteria (Pseudomonas aeruginosa), or saline via fiberoptic bronchoscopy. The 
calves were euthanatized four to six hours following inoculation. Eight 3-month old 
cattle were inoculated in the primary bronchus of the right cranial lung lobe via fiberoptic 
bronchoscopy with pyrogen-free saline, Mannheimia haemolytica LPS-associated peptide 
(LPS-P), M haemolytica lipopolysaccharide or M haemolytica (two cattle per inoculum) 
(5). Twenty-four hours post-inoculation, animals were euthanatized. 
From each animal of each age group (neonatal and young adult), sections of lung were 
taken from each site and fixed in neutral-buffered formalin for immunohistochemical 
detection of AP. Lung tissue from the neonatal calves and one healthy adult cow 
(Icm^/sample, two samples per animal) were frozen immediately in liquid nitrogen and 
stored in a -70°C fireezer for western blot analysis. In addition, BAL fluid was collected 
firom three healthy adult cows. BAL fluids were assessed for AP by ELISA; 
antimicrobial activity of BAL fluids also was assessed. 
1G9-IC2 monoclonal antibody. Anti-anionic peptide IgG was produced by Brogden 
et al. (9) in CFl mice against the synthetic peptide H-DDDDDDD-OH conjugated to 
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keyhole limpet hemocyanin. This peptide was synthesized based on the sequence of AP 
isolated firom sheep BAL fluid (5). 
Western Blot analysis. Lung tissue was homogenized in a chilled saline solution then 
boiled for five minutes after addition of reducing lane marking buffer (a). Twenty 
microliters of a 1:10 dilution (lung sample/IX lane marker buffer) were added per lane. 
Broad range SDS-PAGE molecular weight standards (b) were run in two lanes per gel. 
SDS-PAGE was performed with 4% stacking and 12% resolving pre-cast mini-gels (b), 
run at lOOV for 90 minutes. Proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (c) via electroblotting (30V for 16 hours). Primary antibody (IG9-
IC2) was applied at a concentration of 5ug/ml (1:200 dilution) to the PVDF membranes. 
Secondary antibody was goat anti-mouse IgO conjugated with alkaline phosphatase (d) 
used at 0.5ug/ml (1:2000). The blots were incubated with peroxidase chromagen (d) for 5 
minutes. Western blots were graded by presence or absence of immunoreactive bands; 
molecular weights of bands were estimated by SDS-PAGE molecular weight standards, 
broad-range (b). Lung tissue from a healthy adult cow was included in the event that lung 
tissue of neonatal cattle lacked AP-IR. 
Anionic Peptide immunohistochemistry. Briefly, slides were deparaffinized, rinsed 
with ultrapure water, subjected to antigen retrieval (microwaved for 10 minutes in pH 
10.0 Tris buffer), and then placed in a -20° C freezer for 15 minutes. Slides were washed 
in TNTB buffer (0.05M Tris, 0.85% NaCl, 0.05% Tween, 1% BSA), then incubated with 
mouse anti-AP IgG (1:700) overnight in a humidified chamber at 4° C. Slides were 
rinsed with TNTB the following morning and incubated for 30 minutes at room 
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temperature with biotinylated goat anti-mouse IgG, 1:400 dilution (e). Slides were rinsed 
in wash buffer (f), and then alkaline-phosphatase-conjugated streptavidin (f) was applied 
for 30 minutes. Slides were rinsed and then exposed to chromagen (g) for 18 minutes, 
rinsed, counter-stained (1/4 strength hematoxylin) and coverslipped. Specificity of 
antibody affinity with tissue sections was determined by pre-incubating the primary 
antibody with varying concentrations of synthetic AP. Three types of negative controls 
were used and all lacked immunoreactivity: I) control sections that were not incubated 
with primary antibody, 2) the primary antibody was incubated with the synthetic AP (H-
DDDDDDD-OH) prior to tissue application, 3) mouse pre-immune serum was substituted 
for primary antibody. 
Scoring of AP immunohistochemistry. The cellular distribution of AP-IR was 
assessed and characterized by light microscopy. Intensity of staining was scored on a 
subjective scale whereby 0 = no anionic peptide immunoreactivity (AP-IR); 1 = <10% of 
cells in a 20X field (of bronchi, bronchiole, alveolus, vessel) had AP-IR; 2 = 10-30% of 
cells in a 20X field had AP-IR; 3 = 30-60 of cells in a 20X had AP-IR, and 4= 60-90% of 
cells had AP-IR. 
Detection of anionic peptide in bronciioalveolar lavage fluids. BAL fiuid was 
collected at necropsy of three adult cows. Fifty milliliters of sterile pyrogen-free saline 
was introduced to and removed from the lung lobe via a pipette inserted into the 
bronchus. AP was detected in ±e BAL by ELISA (4). The ELISA assay was completed 
as previously described (2-4). Briefly, wells (h) were incubated with 100 ul surfactant (1 
mg/ml) and 100 ul BAL fluid overnight at 26 C. Wells were washed twice and then 
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incubated with mouse anti-AP antibody 1G9-IC2 at 1 ug/mi for 1 hour at 26 C. The 
wells were washed and incubated with goat anti-mouse IgG conjugated to peroxidase (d), 
washed three times and then incubated with developing reagent (i) for 5 minutes. Plates 
were read at 450 wavelength. Standards contained dilutions of synthesized AP. A 
standardized concentration of urea was used to compare volumes of BAL fluid. 
Antimicrobial activity of BAL. Antimicrobial activity for M haemolytica A1 were 
determined for BAL from calves according to previously described methods (2-4) and 
compared to the MIC of BAL of adult cattle. Briefly, M haemolytica was grown in 
tryptose broth at 37 C for 3 h, pelleted by centrifugation at 5,900 X g for 15 minutes at 4 
C, and resuspended in 0.14 M NaCl. The suspension was adjusted with a Coleman 
spectrophotometer (78% transmittance; 600 nm) 0);to contain 1x10® CFU/ml and were 
diluted 10^ to 10^ CFU/ml with 0.14 M NaCl. Antimicrobial activity was determined by 
a dilution susceptibility test. Percent killed bacteria determined by a calculation [1-(CFU 
in BAL fluids/CFU in saline control mixture)] for BAL fluids was compared to control 
fluid. 
Results 
Western blots, calves and adult cow. In western blots of lung homogenates from all 
six neonatal calves and the adult cow (Figure 1), five bands were seen: 28-30 kDa 
(strongest signal); 31 kDa; variable bands at 45 kDa (calves) and at 35-38 kDa (cow); and 
64 kDa (cow). The 28-30 kDa band is present in all calves regardless of treatment group. 
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Immunohistochemistry. The distribution of AP-IR was similar between neonatal and 
young adult cattle. Intensity of AP-ER was graded subjectively by the scale described in 
Materials and Methods (Table 1). In bronchi, intense staining in the nuclei of individual 
bronchial epithelial cells was present in all age groups (Figure 2A). AP-IR was also 
present in the apical cytoplasm of most cells in the pseudostratified epithelium of 
bronchial mucosa (Figure 2 A, 2B). In most areas of bronchial epithelium, there was 
intense staining (nuclear, cytoplasmic, or both) of multifocal, individual bronchial 
epithelial cells whereas adjacent cells completely lacked staining. Nuclei of multifocal 
cells of the bronchial submucosal glands were immunoreactive for AP; however, 
submucosal gland cells lacked cytoplasmic AP-IR. Inoculation with M haemolytica, 
LPS, or LPS-associated peptide did not alter AP-IR intensity in bronchi of young adult 
cattle. Nuclei of multifocal lymphocytes within the lamina propria and adventitia of 
bronchi were immunoreactive for AP; however, neutrophils within the bronchial lumina 
lacked AP-IR. 
In neonatal and young adult cattle, bronchiolar epithelial nuclei had AP-IR and very 
little to no cytoplasmic staining. AP-IR was present in nuclei of multifocal cells and in 
the apical cytoplasm of bronchiolar mucosa (Figure 2C, 2D). In lungs of young adult 
cattle, the intensity of nuclear staining was decreased markedly in bronchioles that 
contain inflammatory exudate. Both M haemolytica and LPS-inoculated tissue had 
abundant inflammatory exudate, yet fibrinous exudate and neutrophils in the lumen 
lacked AP-IR. 
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Distribution of alveolar AP-ER was similar in neonatal calves and young adults. AP-IR 
was present in the nucleus, and only sporadically present in the cytoplasm of alveolar 
epithelial cells. In all age groups, nuclear AP-IR of arterial and bronchial smooth muscle 
cells was present and there was only rare cytoplasmic AP-IR. AP-IR was distributed 
randomly in the smooth muscle cells and did not have a pattern within the layers of the 
bronchi or in the vascular wall. AP-IR was not altered in alveoli that contained 
inflammatory exudate. 
Concentration and antimicrobial activity of AP in BAL fluid. AP was detected in 
BAL fluid of all calves (mean = 0.32 mM + 0.23) and adult (0.09 mM + 0.03) cattle in 
this study. Standard curve and positive control consisted of the synthesized AP H-
DDDDDDD-OH added to ELISA-negative surfactant. There were no significant 
differences in BAL AP concentrations between groups of calves. 
BAL fluids from calves lacked antimicrobial activity whereas BAL fluid from adult 
cattle had significant antimicrobial activity. In adult cattle, percent killing (n = 11) 
ranged from 23 to 75% and averaged 60.2%. In contrast, percent killing of calf BAL 
fluid was <1%. 
Discussion 
AP-IR is widespread in the lungs of young cattle in both non-inflamed and acutely 
inflamed tissue. The distribution of AP-IR in lung tissue of cattle and the presence of AP 
in BAL fluid of cattle is similar to that of sheep (9), but the concentration of antibody 
required to detect AP-IR in the sheep lung is lower. This may be due to greater avidity of 
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the antibody to ovine AP, the availability of AP in ovine tissue sections, or the amount of 
AP in ovine tissues. Because IG9-IC2 antibody was prepared against a synthetic peptide 
based on ovine AP structure, the antibody may have higher avidity for ovine AP as the 
exact structure of AP from cattle is currently unknown. Bovine AP is thought to be 
similar to ovine AP, but it may have subtle differences. Both species produce AP in the 
respiratory mucosa, indicating that AP is present in a location where antimicrobial 
activity would be most effective against microbial colonization. 
Various proteins, including nucleosomal proteins, contain polyaspartate regions that 
may be detected by the IG9-IC2 monoclonal antibody. For example, nonhistone acidic 
proteins that bind to chromatin, known as the High Mobility Group (HMG) proteins are 
present in the nucleus. These proteins have long stretches of acidic amino acid 
sequences, with some stretches of up to 40 aspartic acid and glutamic acid residues (11). 
The exact protein or proteins that release active forms of AP are not known, nor is the 
cleavage process that liberates active AP. 
The western blots suggest that the AP peptide (as intact zymogen) was present in each 
calf as well as in adult cattle. Mild variations in the intensity of AP-IR on 
immunohistochemical stains could be due to individual variation among the calves, or 
local effects of bacteria or bacterial products too subtle to be recognized by western blot 
analysis. Most importantly, this work documents the presence of AP in bovine lung 
tissue, which has been previously shown only in tissues of sheep and human beings. This 
study also suggests that AP is likely not induced during acute pneumonia. By western 
blot analysis, AP was present in lungs of both pneumonic and non-pneumonic lungs of 
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calves. Furthermore, immunohistochemical detection of AP-IR was not increased in 
intensity or distribution in pneumonic lung tissue, and appeared to decrease in pneumonic 
lung tissue of older animals. The inability to detect increased AP production in acute 
pneumonia contrasts sharply to several other AMPs, including human (3-defensin-2, 
lingual antimicrobial peptide, and tracheal antimicrobial peptide (4, 12, 13,14) which are 
rapidly increased. 
hiterestingly, an inverse correlation may exist between the AP-IR and the acute 
inflammatory response of the lung. This inverse relationship may be part of a primary 
and secondary irmate defense system utilizing both AP and defensins/cathelicidins, 
respectively. For example, AP is already present in high concentrations in the B AL fluid 
of sheep and humans (5, 7, 9). This contributes to the anionic microenvironment on 
alveolar surfaces that is refractory to bacterial colonization and infection. AP 
concentration may be in a non-replenished state. Second, the AP defense system may 
collapse during an overwhelming infection and in an acute inflammatory response when 
AP stores are depleted. At this point, the defensins are being regionally transcribed and 
up regulated to take the place of the AP. This biphasic overlapping system is reasonable 
from the standpoint of host defense. First, up-regulation of both systems simultaneously 
would be physiologically redundant. Second, up-regulation of both systems 
simultaneously may result in an in situ charge-induced inactivation of cationic and 
anionic antimicrobial peptides. 
Work in this study suggests that 1) AP are produced by the respiratory tract of cattle, 2) 
the distribution of AP in the lung is similar between cattle and sheep, 3) AP production is 
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likely constitutive, and 4) the presence of AP in cells is not decreased at four hours after 
inoculation, but is reduced twenty-four hours after inoculation. 
Footnotes 
^ImmunoPure® Reducing Lane Marker Buffer, Pierce, Rockford, Illinois, USA 
"^BioRad®, Hercules, California, USA 
•^Immobilon-P, Millipore Corporation, Bedford, Massachusetts, USA 
''Kirkegaard & Perry Laboratories, Gaithersburg, Maryland, USA 
"Vector, Burlingname, California, USA 
'BioGenex, San Ramon, California, USA 
'Vector Red, Vector, Burlingname, Califomia, USA 
"Tnimulon-l plates, Dynatech Laboratories, Chantilly Virginia, USA 
'TMB Microwell peroxidase substrate, fCirkegaard & Perry Laboratories 
^Bacharach Instrument Company 
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Table 1. Inflammation vs. intensity of AP-IR in lungs of young adult cattle twenty-four 
hours after intrabronchial inoculation of Mannheimia (Pasteurella) haemolytica. 
Species/inoculation* Inflammatory lesion AP-IR Intensity 
Bovine/pbs 0 +++ 
Bovine/lap + +++ 
Bovine/lps ++ ++ 
Bovine/ph ++ -H-
*Cattle groups with two animals per inoculation received either pyrogen-free saline 
(pbs), lipopolysaccharide-associated peptide of M. haemolytica (lap), lipopolysaccharide 
from M haemolytica, or live M haemolytica. AP-IR intensity and the degree of the 
inflammatory lesion were assessed by a pre-determined, subjective scoring system (i.e. 
0 = no anionic peptide immunoreactivity (AP-IR); 1 = <10% of cells in a 20X field had 
AP-IR; 2 = 10-30% of cells in a 20X field had AP-IR; 3 = 30-60 of cells in a 20X had 
AP-IR, and 4= 60-90% of cells had AP-IR.). 
5 6 7 8 
Figure 1. Western blots: Immunoreactivi^ of AP monoclonal antibody to larger proteins 
(range 35 kOa to 64 kDa), perhaps zymogens, from homogenized lung tissue of calves 
and an adult cow, as well as immunoreactivity to the typical 31 lc£)a frament. Proteins 
were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and 
transferred to polyvinylidene difluoride membranes. Monoclonal antibody IG9-IC2 (anti-
anionic peptide antibody) was used for immunoblotting. Lane I: Calf 3, Lane 2: Calf 2, 
Lane 3; Calf I, std. Lane 4; adult cow. Lane S: Calf 6, Lane 6, Calf S, Lane 7: Calf 4, 
Lane 8: adult cow. 
Facing page: 
Figure 2. Immunohistochemical detection of AP with an anti-anionic peptide (AP) monoclonal antibody in lung tissue 
from calves. Red staining in cells represents AP immunoreactivity (AP-IR). n = neutrophils; b = bronchial or 
bronchiolar epithelium. A) Bronchus, neonatal calf AP-IR is present in multifocal nuclei and cytoplasm of bronchial 
epithelial cells. Bar= lOOum. B) Bronchus, higher magnification. Bronchial epithelial cells have multifocal 
cytoplasmic AP-IR Bar = 50um, C) Bronchiole, neonatal calf. Multifocal bronchiolar epithelial cells have cytoplasmic 
and/or nuclear AP-IR. Bar = lOOum. D) Bronchiole, neonatal calf with suppurative bronchiolitis. There is multifocal 
nuclear AP-IR in bronchiolar epithelial cells, but luminal exudate is not immunoreactive. Bar = lOOum. 
p » 'tw" 
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CHAPTER THREE. ONTOGENY AND EXTRAPULMONARY DISTRIBUTION 
OF ANIONIC PEPTIDE IN THE BOVINE 
A paper to be submitted to the journal Veterinary Pathology 
Amanda J. Fales-Williams, Kim A. Brogden, Elise Huffinan, Jack Gallup, 
Mark R. Ackermann 
Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State 
University (AJFW, EH, JG, MRA), and Respiratory Diseases Unit, National Animal 
Disease Center, Ames, Iowa (KAB) 
Abstract 
Anionic peptide (AP), a small peptide of seven aspartic acid residues, is a recently 
described antimicrobial peptide detected in ovine, bovine and human lung tissue. The 
age at which AP is first produced is unknown, thus AP production was compared in the 
respiratory tract of one fetal bovine, three neonatal calves, and three adult cows. Fetal 
tissues (lung, trachea, and nasal turbinate) were more intensely immunoreactive for AP 
than calves and adult cattle, with minor variation between calves and adults. AP 
immunoreactivity has been documented in the lung of neonatal cattle, but the presence 
and distribution of AP in tissues other than the lung is poorly understood. To assess 
presence of AP outside of the respiratory tract, selected tissues were collected for 
immunohistochemistry and western blots from three healthy adult cows. AP production 
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appears to be limited to the respiratory tract with a few exceptions. Extrapulmonary 
expression was present in the cytoplasm of gall bladder epithelium and root sheath 
epithelium of hair follicles in the skin. Nuclear immunoreactivity of tubular epithelium 
predominated in the kidney, although there was limited, multifocal areas of cells with 
cytoplasmic immunoreactivity. Mucosal surfaces composed of stratified squamous 
epithelium lacked immunoreactivity for AP. Additional tissues (rumen, small and large 
intestine) had nuclear staining of epithelial cells. Western blot analysis of all tissues 
demonstrated multiple bands ranging from 6.5 kDa to 66.0 kDa, with a consistent 31.0 
kDa band. This supports the suggestion that AP may be part of a larger molecule. This 
work demonstrates that AP is present in highest intensity in fetal lung epithelial cells and 
that AP is produced in tissues outside of the respiratory tract in the adult bovine. 
Kev Words: Bovine, pulmonary, antimicrobial peptides, anionic peptide, follicular 
epithelium, gall bladder, ontogeny, immunohistochemistry 
Introduction 
A feature of many recently described antimicrobial peptides, such as a- and P-
defensins, cathelicidins, and lysozyme, is the variability of cell types and tissues in which 
they are expressed. Production of some antimicrobial peptides is specifically limited to 
regions within an organ, while others are produced in multiple tissues throughout the 
body. Some groups of antimicrobial peptides are increased in sites of inflammation, such 
as human P-defensin-2,' while human p-defensin-1 is produced constitutively." 
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Anionic peptide (AP), a small homopolymeric peptide of seven aspartic acid residues 
with antimicrobial activity, has been described in the lung and bronchoalveolar lavage 
(BAL) fluid of sheep and cattle."'"* AP is distinct from many antimicrobial peptides for 
the following reasons: it is a smaller size, it has an anionic charge due to homopolymeric 
regions of aspartate, it has a requirement of zinc as a cofactor for bactericidal activity, and 
it is present in pulmonary surfactant.'*" It has been suggested that AP may be a product 
of post-transitional cleavage of a larger peptide, such as a zymogen.^ The identity of the 
mature protein product from which AP is cleaved is not yet known. 
Similar to other antimicrobial peptides, AP is bactericidal for Gram-positive and 
Gram-negative organisms with efficacy that is inversely proportionate to the number of 
aspartate residues in the peptide.' " The mechanism of bacterial killing has not been fully 
elucidated but is thought to involve the bacterial uptake of AP and zinc. AP bactericidal 
activity is inhibited in the presence of phosphates or EDTA." Recent work indicates the 
presence of AP-containing proteins in trachea, nasal epithelium, liver and small intestine 
of sheep."* Degenerate oligonucleotides were synthesized to identify precursor genes for 
AP in sheep genomic DNA; these probes hybridized with larger sequences, further 
indicating the likelihood that AP is a precursor portion of a zymogen."* Although AP-like 
molecules have been demonstrated by immunohistochemistry in the lung of cattle, sheep 
and human,"*' ® the distribution of extrapulmonary AP production in the ruminant has yet 
to be determined. 
Our first objective in this study was to determine in which developmental stage AP 
production occurs in the lung and to compare AP production of the respiratory tract in 
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tissues from three different age groups (fetal, neonatal, and adult). Ontogeny of other 
antimicrobial peptides is variable. Mouse cryptdins, a-defensins produced by intestine 
Paneth cells, are present in fetal ileum.^ In humans, genes for enteric a-defensins HD-5 
and HD-6 are expressed in differential patterns within the small and large intestine during 
early gestation,® with higher production of HD-5 than HD-6 throughout gestation. The 
mechanisms that induce increased AP production are unknown. Tissue and cellular 
inflammatory state may determine the amount of AP produced. Previous studies indicate 
diat AP production is not increased in areas of acute inflammation.^ Our second 
objective for this study was to assess the distribution of extrapulmonary AP production 
among tissues with potential exposure to bacteria (gastrointestinal tract, urinary tract, 
biliary tree, skin). AP production was detected by immunohistochemistry and western 
blot analysis in both studies. 
IVIaterial and Methods 
Three healthy adult dairy cows were euthanatized and tissues were collected 
immediately. One of the cows was pregnant with a near term male fetus. Sections of 
tissues were taken from each organ and fixed in neutral-buffered formalin for 
immunohistochemical detection of AP. Additionally, tissues for western blots 
(IcmVsample, two samples per animal) were frozen immediately in liquid nitrogen, then 
stored in a -70°C freezer for western blot analysis. Three healthy neonatal Holstein 
calves were deprived of colostrum and brought to the Iowa State University Laboratory 
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Animal Resources facility within 24 hours of birth. These calves were euthanatized at 
this time and tissues were collected for western blots and immunohistochemistry. 
IG9-IC2 monoclonal antibody. Anti-AP IgG (IG9-1C2) was produced in CFl mice 
against the synthetic peptide H-DDDDDDD-OH conjugated to keyhole limpet 
hemocyanin."* 
Anionic Peptide Immunohistochemistry. Briefly, slides were deparafflnized and 
subjected to antigen retrieval (microwaved for 5 minutes in pH 6.0 citrate buffer, then 
cooled in a -20 C freezer for 15 minutes). This is in contrast to previously studies, in 
which the antigen retrieval process consisted of microwaving slides for 10 minutes in pH 
10.0 buffer. Slides were washed in TNTB buffer (0.05M Tris, 0.85% NaCl, 0.05% 
Tween 20,1% BSA), then incubated with 1G9-IC2 mouse anti-AP IgG, 1:700 dilution, 
overnight in a humidified chamber at 4° C. Slides were rinsed with TNTB the following 
morning and incubated for 30 minutes at room temperature with biotinylated goat anti-
mouse IgG, 1:400 dilution (Vector, Burlingname, CA). Slides were rinsed in BioGenex 
wash buffer, then alkaline-phosphatase-conjugated streptavidin (BioGenex, San Ramon, 
CA) was applied for 30 minutes. Slides were rinsed and then exposed to chromagen 
(Vector Red) for 10 to 18 minutes, rinsed, counter-stained and coverslipped. Nonspecific 
reactivity due to endogenous alkaline phosphatase activity of the intestinal tissues was 
blocked by 2 minute incubation with 20% glacial acetic acid at 4° C . Endogenous 
alkaline phosphatase of all tissues was blocked by addition of 2.5 mM levamisole to the 
chromagen buffer. Specificity of antibody affinity with tissue sections was determined by 
pre-incubating the primary antibody with varying concentrations of synthetic AP. Two 
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types of negative controls were used. Control sections that were not incubated with 
primary antibody did not have immunoreactivity. When using nonspecific mouse IgG as 
a negative control, there was no immunoreactivity except where noted. 
Scoring of AP immunohistochemistry. The cellular distribution and intensity of AP-
immunoreactivity was assessed and characterized by light microscopy. Distribution of 
staining was scored on a subjective scale whereby 0 = no anionic peptide 
immunoreactivity (AP-IR); 1 = <10% of cells in a 40X field (of epithelial cells) had AP-
IR; 2 = 10-30% of cells In a 40X field had AP-IR; 3 = 30-60 of cells in a 40X had AP-IR, 
and 4= 60-90% of cells had AP-IR. Intensity of AP-IR in epithelial cells was also scored 
on a subjective scale whereby 0 = no AP-IR, 1 = nuclear staining only, 2 = multifocal, 
mild cytoplasmic and diffuse nuclear staining, 3 = diffuse, light red cytoplasmic AP-IR, 
with or without nuclear staining, and 4 = diffuse, bright red cytoplasmic AP-IR. 
Statistical Analysis. The results of the subjectively scored slides were analyzed by the 
Kruskal-Wallis test. All calculation were done with SAS statistical software (SAS 
histitute, Gary, NC). Results were classified as significant at P < 0.05. 
Western Blot Analysis. Tissues were homogenized in a chilled saline solution, then 
boiled for five minutes with Pierce ImmunoPure® Reducing Lane Marker Buffer. SDS-
Polyacrylamide gel electrophoresis was performed with 4% stacking and 12% resolving 
pre-cast mini-gels (BioRad®) at lOOV for 90 minutes. Proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes via electroblotting at 30V for 16 hours. 
Primary antibody (IG9-IC2) was applied at a concentration of 5ug/ml (1:200 dilution) to 
the PVDF membranes. Secondary antibody was goat anti-mouse IgG conjugated with 
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alkaline phosphatase. Chromagen was 4CN Membrane Peroxidase Substrate System 
(Kirkegaard and Perry Laboratories, Gaithersburg, MD). Western blots were graded by 
presence or absence of immunoreactive bands; molecular weights of bands were 
estimated by SDS-PAGE molecular weight standards, broad-range (BioRad Laboratories, 
Hercules, CA). 
Results 
Ontogeny in respiratory tissues. There was a striking difference in the distribution and 
staining intensity for anionic peptide (AP) in the fetal tissues compared to either the 
neonatal or adult respiratory tissues (Table 1). Tracheal epithelial cells and submucosal 
glands of the fetal tracheal epithelium had diffuse, granular cytoplasmic AP-
immunoreactivity (Fig. 1 A) compared to neonatal and adult tracheal epithelial cells which 
lacked cytoplasmic staining (Fig. IB, IC). This pattern of immunoreactivity intensity 
was similar in lung and nasal mucosa (data not shown). In the fetal lung, there was 
diffuse AP-immunoreactivity in alveolar, bronchial, and bronchial epithelial cells. There 
was a similar pattern of staining in fetal nasal mucosal epithelial cells, and adult and 
neonatal nasal mucosal epithelial cells lacked cytoplasmic AP-immunoreactivity. 
Although there were apparent differences in the intensity of AP-immunoreactivity 
between the three developmental groups, there were no statistical differences in the 
subjective scores as determined by the Kruskai-Wallis test. 
AP-like proteins were present in fetal respiratory tissues as demonstrated by western 
blot analysis. A 31.0 kDa band was present in lung, nasal turbinate, and trachea from the 
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single fetus (Fig. 2). Similarly, a 31.0 kDa band was present in lung, nasal turbinate and 
trachea of the adult cows (Fig. 3), with inconsistent, faint bands at 45.0 kDa in nasal 
turbinate and trachea. In tissues from neonatal calves, a 31.0 kDa band was present only 
in lung tissue, but not trachea and nasal turbinate (data not shown). 
Extrapulmonary AP production. Staining for anionic peptide immunoreactivity (AP-
IR) was present in epithelial cell cytoplasm and nuclei of the following tissues: gall 
bladder root sheath epithelium of hair follicles and uterus. In the gall bladder, 
cytoplasmic immunoreactivity was present in columnar epithelial cells, as well as in 
multifocal individual lymphocytes within submucosal lymphocytic aggregates. 
Incubation of mouse IgG on a serial section had nonspecific cytoplasmic staining of 
submucosal glandular epithelial cells, but not in columnar surface epithelial cells. In hair 
follicles of both adult and fetal skin, there was intense immunoreactivity for AP in the 
root sheath epithelium of hair follicles in anagen phase (Fig. 4A, 4B). Incubation of skin 
sections with mouse IgG did not result in immunoreactivity (data not shown). AP 
immunoreactivity was present in the cytoplasm of both surface epithelial and submucosal 
gland cells of the uterus (Fig. 5A, 5B). There was no immunoreactivity when serial 
sections were incubated with mouse IgG (Fig. 5C). 
The pattern and intensity of staining of stratified squamous epithelium, such as glossal, 
buccal, and esophageal mucosae, were identical to sections incubated with mouse anti-
IgG and thus considered nonspecific staining. Ruminal, enteric (jejunum and ileum), 
cecal and colonic epithelium had nuclear AP-IR, with occasional staining of cytoplasm of 
individual cells in colonic glands. There was no staining of hepatocytes or intrahepatic 
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bile duct epithelium, urinary bladder or renal pelvis urothelium, or abomasum. The 
immunohistochemical results are summarized in Table 2. 
Immunoreactive bands were present in most tissues tested by SDS-PAGE and 
immunoblotting procedures (Table 3). This included tissues in which only nuclear 
immunoreactivity or no immunoreactivity was detected by immimohistochemistry (small 
and large intestine, rectum, abomasum, cheek, tongue, esophagus, liver). A 31 kDa 
single or double band was the most consistent band among the different tissues (Table 3). 
Western blots of the gall bladder, kidney, and uterus (Fig. 6), are typical of most tissues 
assessed. Variability in the 31.0 kDa band between animals was rare, although there was 
slight variability in the number and size of larger bands among different tissues and 
animals. There is only one instance in which tissues with immunohistochemical 
detection of AP failed to have detection of AP by immunoblotting. This occurred with 
skin of adult animals, although there was immuno-detection of AP in fetal skin tissue by 
Western blots (Fig. 7). 
Discussion 
In this study, we examined tissues by immunohistochemistry and westem blots for 
immunoreactivity for Anionic Peptide (AP). In the small number of animals of each age 
group examined, AP is present in a greater number of cells in fetal tissues than in 
neonatal or adult cattle. Westem blots confirm the presence of AP in fetal respiratory 
tissues, adult respiratory tissues, and neonatal lung tissue. Both of the procedures 
employed (immunohistochemistry and westem blot analysis) are semi-quantitative. 
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Therefore, these data do not confirm an absolute greater production of AP by fetal 
respiratory tissues. However, these findings support a subjective increase in production 
of AP (or its parent zymogen compound) by immature cells, or that AP (or zymogen) is 
produced early in cellular development. If AP is present in higher quantities in the fetus, 
this may represent a rudimentary, and most likely ineffective, antimicrobial defense of the 
upper and lower fetal respiratory tract, or an immature parent molecule that is not 
degraded or processed to release AP. 
Our second objective was to ascertain the presence of AP at mucosal sites, other than 
the respiratory tract, that are exposed to bacteria. This study demonstrates that AP is 
present at few sites outside of the respiratory tract, but not at all mucosal sites with 
exposure to microflora. Cytoplasmic immunoreactivity for AP was present in the gall 
bladder, skin, and uterus of adult tissues. The presence of AP-immunoreactivity in gall 
bladder epithelium suggests that AP is stored and released to the intestinal lumen with 
bile. The specificity of AP-immunoreactivity for irmer root sheath epithelium in both 
adult and fetal skin is an unexpected finding. Anionic peptide was detected by western 
blotting technique of fetal skin but not in adult skin. One explanation for this may be that 
the quantity of AP is relatively higher in fetal skin as there are comparatively more hair 
follicles in anagen phase in fetal skin than in adult skin. Anionic peptide 
immunoreactivity was intense in the cytoplasm of endometrial surface epithelium and 
glands. The widespread presence of AP-immunoreactivity in uterine epithelium may 
reflect hormonal up-regulation of AP, or its larger zymogen component. Nuclear 
immunoreactivity was also present in gastrointestinal epithelium, including rumen, 
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urinary bladder, jejunum, ileum, cecum, and colon; however, the importance of AP within 
the nucleus of cells is difficult to assess. Cells of stratified squamous epithelium, as 
present in skin, tongue, cheek, and esophagus, does not appear to produce AP. 
Some of the immunohistochemical results in this study are in contrast to results 
obtained with an earlier antigen retrieval protocol used in a previous study in which 
tissues were subjected to boiling for 10 minutes in a pH 10.0 buffer.^ For example, there 
is decreased nuclear immunoreactivity in virtually all tissues using the antigen retrieval 
process of boiling for 5 minutes in a pH 6.0 buffer. We adopted this new protocol for all 
tissues studied in this manuscript, as we noted increased cytoplasmic immunoreactivity 
with decreased nuclear staining. 
Challenges exist in interpreting the nuclear staining associated with this monoclonal 
antibody. A class of nucleosomal non-histone proteins, known as high-mobility-group 
(HMG) proteins, are acidic proteins with stretches of up to 35 glumatic acid and aspartic 
acid residues.'® It is possible that the IG9-IC2 monoclonal antibody is recognizing these 
acidic portions of nucleosomal proteins rather than the pre-profragment of the yet-to-be 
identified zymogen. Therefore, whether nuclear staining, void of cytoplasmic staining, 
can be associated with AP production by these tissues (hepatocytes, epithelial cells of 
rumen, small intestine, large intestine) is not yet known. 
Western blots detected immunoreactive bands in the tissues listed in Table I. The 
typical molecular weight of these bands, 3 l.O kilodaltons, greatly exceeds the actual 
molecular weight of the anionic peptides isolated by Brogden et ai., as these range in 
weight firom 722 to 824 daltons.^ We attribute this difference to the presence of intact. 
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unprocessed zymogens within solid tissues. We have not detected the peptide 
independent of the zymogen by western blot at this time. 
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Table 1. Ontogeny of AP production in bovine respiratory tissues. Distribution and 
intensity of AP-imraunoreactivity were scored whereby 0 = no anionic peptide 
immunoreactivity (AP-IR); I = <10% of ceils in a 40X field (of epithelial cells) had AP-
IR; 2 = 10-30% of cells in a 40X field had AP-IR; 3 = 30-60% of cells in a 40X field had 
AP-IR, and 4= 60-90% of cells in a 40X field had AP-IR. Intensity of AP-IR in epithelial 
cells was also scored on a subjective scale whereby 0 = no AP-IR, 1 = nuclear staining 
only, 2 = multifocal, mild cytoplasmic and diffuse nuclear staining, 3 = diffuse, light red 
cytoplasmic AP-IR, with or without nuclear staining, and 4 = diffuse, bright red 
cytoplasmic AP-IR. Individual scores of each animal are presented by tissue. 
A. Distribution and intensity of AP production in epithelial cells of nasal mucosa 
Nasal mucosa Distribution of AP Intensity of AP-IR 
Fetus (n = 1) 4 J 
Neonate (n=l)  2 2 
Adult (n = 3) 1/1/2 2/1/2 
3. Distribution and intensity of AP production in tracheal epithelial cells 
Trachea Distribution of AP Intensity of AP-IR 
Fetus (n=l)  4 4 
Neonate (n = 3) 1/0/1 1/0/1 
Adult (n = 2) 2/0 2/0 
C. Distribution and intensity of AP production in epithelial cells of bronchi, bronchioles, 
and alveoli 
Lung Distribution of AP Intensity of AP-IR 
Fetus (n= 1)  4 4 
Neonate (n = 2) 1.5/3 1/1 
Adult (n = 3) 2/2/1 1/1.5/1 
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Table 2. Distribution and intensity of AP in extrapulmonary bovine tissues. 
Distribution and intensity of AP-immunoreactivity were scored whereby 0 = no anionic 
peptide immunoreactivity (AP-IR); I = <10% of ceils in a 40X field (of epithelial cells) 
had AP-IR; 2 = 10-30% of cells in a 40X field had AP-IR; 3 = 30-60% of cells in a 40X 
field had AP-IR, and 4= 60-90% of cells in a 40X field had AP-IR. Intensity of AP-IR in 
epithelial cells was also scored on a subjective scale whereby 0 = no AP-IR, 1 = nuclear 
staining only, 2 = multifocal, mild cytoplasmic and diffuse nuclear staining, 3 = diffuse, 
light red cytoplasmic AP-IR, with or without nuclear staining, and 4 = diffuse, bright red 
cytoplasmic AP-IR. Individual scores of each animal are presented by tissue. 
Tissue Distribution of AP Intensity of AP 
Skin (n = 4) only in follicular epithelium -/3/4/4' 
Cheek (n = 4) 1/1/1/1" l / l / l / l "  
Tongue (n = 3) 1/1/1" l / l / l "  
Esophagus(n = 4) l / l / l / l "  l / l / l / l "  
Rumen (n = 4) l / l / l / l  l / l / l / l  
Abomasum (n = 1) 0 0 
Jejunum (n = 4) 1/1/1/1 1/1/2/1 
Proximal ileum (n = 3) l / l / I  l / l / l  
Cecum (n = 4) 1/1/1/1" 1/2/1/1 
Colon (n = 3) l / l / l '  l / l / l  
Rectum (n = 3) l / l / l  1/2/1 
Liver (n = 3) 0/1/0 0/1/0 
Kidney (n = 3) 1/2/2 1/3/2 
Uterus (n = 2) 2/4 2/3 
Gall bladder (n = I) 4 J 
Urinary bladder (n = 2) 1/0 I/O 
* Tissue loss of one slide prevents evaluation. 
Staining pattern with anti-AP antibody is the same as pattern with non-specific mouse IgG. 
' AP-immunoreactivity is present in cytoplasm of individual cells of colonic glands only. 
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Table 3. Detection of immunoreactivity for anionic peptide in non-respiratory 
tissues, adult bovine. Tissues were assessed by western blot analysis using the 
monoclonal antibody Ig9-lC2. A band at 31.0 kDa was present in most tissues unless 
otherwise noted. Additional bands at different molecular weights were present in some 
tissues, as listed in the third column. 
Tissue 31.0 kDa band present in 3 cows Additional bands 
Skin Not detected 
Cheek Single 
Tongue Single 66.0 kDa 
Esophagus Single 45.0 kDa 
Rumen Single 
Abomasum Double 
Duodenum Single band in 2/3 cows 
Jejunum Double 
Prox. ileum Single band in 1/3 cows 
Cecum Single band in 1/3 cows 
Colon Not detected 
Rectum Double 
Liver Double 6.5 kDa band in 1 cow 
Kidney Double 6.5,40, 45, 66 kDa in 1 cow 
Uterus Double (2/2 cows) 45 kDa 
Gall bladder Double (1/1 cow) 35 kDa 
Urinary 
bladder 
Single (1/1 cow) 
lA 
Figure 1. Ontogeny of Anionic Peptide (AP) in tlie bovine respiratory tract. Tissues were 
incubated with anti-AP monoclonal antibodies, 1:700 concentration. A) Fetal trachea; AP-
immunoreactivity is present in cytoplasm of tracheal epithelial cells and submucosal gland 
cells. Magnification 64X. B) Trachea, neonatal calf. AP-immunoreactivity is present in 
the cytoplasm of rare tracheal epithelial cells. Magnification 64X. Q Trachea, adult bovine. 






Figure 2. Western Mots^ fetal tissues 
A single band is piesent in all lanes (nasal turboiate, trachea, and lung) at 







A single band is present at ornear 31.0 kD in alllanes (hmg fiom two 
cows, nasal turbinate, and trachea). 
Figure 4. Detection of Anionic Peptide (AP) in haired skin of catde. Presence of red stain indicates location of AP-inununcweactivity. 
A) AP-inununcKeactivity is present in the inner root sheath epithelium of hair follkles, skin fix)m a fetal bovine. 64X magnification. 
B) AP-immunoreactivity in anagen phase hair follicle of an adult bovine. AP is present in the root sheath epithelium. I60X 
magnification. 
Facing page: 
Figure 5. Uterus, adult cow. Presence of Anionic Peptide (AP) in epithelial cells of the endometrium; surface 
epithelium and endometrial glands. A) Submucosal glands of uterus have cytoplasmic AP-immunoreactivity. 64X 
magnification. B) AP-immunoreactivity is present in cells composing surface epithelium and endometrial glands. 
Cytoplasmic AP-immunoreactivity is present in both types of cells. Magnification 64X. C) There is no 
immunoreactivity when tissues are incubated with non-specific mouse IgG antibodies. Magnification 64X. 





Figure <1. Western bkHs, gall bladder, kidney, utenis. A 31.0 double band is Dnmunoreactive using 
anti-APnionocok}nalantibo(fy in the gall bladder and uterus lanes. There is variability among two 
adult cows in number of bands (xesent in the kidn^, although 31.OkD band is constant 
45.0 kD 
31.0 kD 
I 2 3 
21.5 kD 
•vix-v. 
F^ ure7. Western bkitsofskinfiom adult cattle, calf and fetus, bnmunoieactive bands are 
present in skin fixmcalfandfetu^ but not in skin fiom adult cows. Lung tissue fiom an 
adult cow is included for comparisoQoftypical weight of AP-immunoreactive bands. 
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CHAPTER FOUR. CHANGES IN ANIONIC PEPTIDE IMMUNOREACTIVITY 
INTENSITY DURING THE INITIATION AND PROGRESSION OF LUNG 
LESIONS IN OVINE MANNHEIMIA (PASTEURELLA) HAEMOLYTICA 
PNEUMONIA 
A paper to be submitted to the journal Veterinary Pathology 
Amanda J. Fales-Williams, Rafael Ramirez-Romero, Kim A. Brogden, and 
Mark R. Ackermann 
Abstract 
Anionic peptide (AP) is a small, antimicrobial peptide composed of seven aspartic acid 
residues. AP is produced in the lung of sheep, cattle and humans and has been detected 
in bronchoalveolar lavage fluid of sheep and humans. AP production is not increased in 
areas of acute inflammation. The objective of this study was to compare the degree of 
anionic peptide production in acute, subacute, and chronic lesions of bronchopneumonia. 
Mannheimia (Pasteurella) haemolytica was inoculated intrabronchially by fiber-optic 
bronchoscopy in eighteen mixed breed sheep of both sexes, 3 months of age. The sheep 
were euthanatized at days 1,15, and 45 after inoculation (n=3, each group). Control 
animals received saline by the same procedure and were killed at the same time points 
(n=3, each group). Additionally, the left (non-inoculated) contralateral lung in bacteria-
inoculated animals were collected as controls. Twenty-four hours after bacterial 
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inoculation, the lungs had severe fibrinopurulent bronchopneumonia with multifocal, 
extensive coagulative necrosis and hemorrhage. In the subacute group (duration of 15 
days following inoculation), the most prominent lesion was necrosuppurative 
bronchiectasis with multifocal areas of bronchiolar epithelial hyperplasia. In the chronic 
group (45 day interval between inoculation and euthanasia), there was more pronounced 
bronchiolar hyperplasia and bronchiolitis fibrosa obliterans. Mannheimia haemolytica 
was isolated only from the lungs of the acute and subacute groups, but not from lambs in 
the chronic group. In lungs of sheep from the postinoculation day 1 group with either 
saline or bacteria inoculation, AP immunoreactivity was present in low levels in the 
cytoplasm of multifocal bronchiolar epithelial cells. In both groups of bacterial 
postinoculation day 15 and 45, there was intense AP-immunoreactivity in the cytoplasm 
of hyperplastic bronchiolar and type II alveolar cells. Epithelial hyperplasia and the 
pattern of intense immunoreactivity were not present in saline control lambs, or in the 
sections of lung lobes contralateral to inoculated lobes. This is the first report of the 
pattern of AP-immunoreactivity in lesions of chronic pneumonic pasteurellosis. 
Key words: immunohistochemistry; Mannheimia (Pasteurella) haemolytica; pneumonic 




Anionic peptide (AP) is a small homopolymeric peptide of seven aspartic acid residues 
with antimicrobial activity that has been detected in the lung and BAL fluid of sheep and 
cattle."*' ® AP is distinct from many antimicrobial peptides for the following reasons: it 
has a smaller size, it has an anionic charge due to homopolymeric regions of aspartate, it 
has a requirement of zinc as a cofactor tor bactericidal activity, and it is present in 
pulmonary surfactant.^' "* It has been suggested that AP may be a product of post-
transitional cleavage of a larger peptide, such as a zymogen;^ however, the identity of the 
mature protein product from which AP is cleaved is not yet known. The objective of this 
work was to determine the progression of AP production in acute, subacute and chronic 
pneumonia. 
The limited effectiveness of vaccination and antibiotic therapies in prevention and 
treatment of M haemolytica pneumonia underscores the need for additional approaches 
in reducing bacterial colonization and infection. The innate immune system is becoming 
increasingly appreciated in its role in inhibiting bacterial colonization of the respiratory 
tract. Antimicrobial peptides serve as a part of the innate immune system, potentially 
reducing bacterial numbers nonspecifically and therefore limiting bacterial colonization.^* 
' '•Most antimicrobial peptides are microbicidal through the formation of pores 
within microbial membranes." A wide range of bacteria are susceptible to antimicrobial 
peptides, including Gram-positive and Gram-negative bacteria and mycobacteria. Some 
antimicrobial peptides are upregulated in response to lipopolysaccharide (LPS) and other 
mediators of inflammation,'^ while others are produced constitutively." One 
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biological strategy against bacterial colonization and infection that may prove more 
effective than vaccination alone is the up-regulation of antimicrobial peptides in 
combination with vaccination. This strategy would prime both the innate and active 
immune defenses. 
The pathogenesis of the severe lung damage that characterizes pneumonic 
pasteurellosis is still poorly understood and most of the studies have emphasized the 
pathogenic mechanisms operating during the acute stage of this pneumonic syndrome.'^ 
However, the lung lesions that remain during the sub-acute and chronic stages are 
responsible for the decreased productivity of affected animals. While acute pneumonic 
pasteurellosis can result in the death of ruminants, lesions of pneumonic pasteurellosis 
also cause losses to producers due to poor feed to weight conversion. 
Production of AP had been assessed in cattle and sheep in acutely inflamed or non-
inflamed tissues.^'' The time from inoculation to euthanasia in previous studies ranged 
from six to 24 hours. There was no difference detected in the amount or distribution of 
A? expression between acutely inflamed and healthy tissue and no increase of AP 
production as can be seen with other, inducible types of antimicrobial peptides. In this 
study, we assessed the distribution of AP expression in acute, subacute, and chronic 
lesions of M haemolytica infection in the lung of sheep. Three-month old lambs were 
inoculated by intrabronchial administration of M haemolytica or saline, and then 
euthanatized at one day, fifteen days, or forty-five days following inoculation. 
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Material and Methods 
Experimental animals. Eighteen sheep, of both sexes and mixed breed, three months 
old, were obtained from Iowa State University, Laboratory Animal Resources. The 
animals were maintained in isolation rooms in accordance with the procedures approved 
by the American Association of Laboratory Animal Care. After 24 hours, the animals 
were randomly assigned to two large groups; one group received Mannheimia 
(Pasteurella) haemolytica while the other received saline. Subsequently, these large 
groups were subdivided in accordance to the time of sacrifice at 1, 15, and 45 days after 
inoculation. This arrangement gave six groups, each one with three animals. 
Inoculation. Mannheimia haemolytica (strain 82/25; originally recovered from a 
natural case of pneumonic pasteurellosis in sheep) was grown in tryptose broth medium 
to achieve 1x10® colony-forming units/ml. Inocula of either bacterial broth or pyrogen-
free saline, 5 mis, were introduced into the right cranial lobe bronchus via fiber-optic 
bronchoscopy. 
Euthanasia and collection of lung samples. Animals were euthanatized with an 
intravenous overdose of sodium pentobarbital. The samples collected included the site of 
inoculum deposition in the right lung; additionally, from those animals that received the 
bacterial inoculum, the equivalent site in the non-inoculated (left) lung, were also 
collected. Samples were obtained in duplicate and were fixed by immersion in 10% 
neutral buffered formalin (48 h at room temperature). 
Immunohistochemistry. Slides were deparaffinized and subjected to antigen 
retrieval (microwaved for 5 minutes in pH 6.0 citrate buffer, then cooled in a -20 C 
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freezer for 15 minutes). Slides were washed in TNTB buffer (0.05M Tris, 0.85% NaCl, 
0.05% Tween 20,1% BSA), then incubated with IG9-IC2 mouse anti-AP IgG, 1:1000 
dilution, overnight in a humidified chamber at 4° C. Anti-AP IgG (IG9-IC2) was 
produced in CFl mice against the synthetic peptide H-DDDDDDD-OH conjugated to 
keyhole limpet hemocyanin.^ Slides were rinsed with TNTB the following morning and 
incubated for 30 minutes at room temperature with biotinylated goat anti-mouse IgG, 
1 ;400 dilution (Vector, Burlingname, CA). Slides were rinsed in BioGenex wash buffer, 
then alkaline-phosphatase-conjugated streptavidin (BioGenex, San Ramon, CA) was 
applied for 30 minutes. Slides were rinsed and then exposed to chromagen (Vector Red) 
for 10 to 18 minutes, rinsed, counter-stained and coverslipped. Specificity of antibody 
affinity with tissue sections was determined by pre-incubating the primary antibody with 
varying concentrations of synthetic AP. Two types of negative controls were used. 
Control sections, which were not incubated with primary antibody, did not have 
immunoreactivity. When using nonspecific mouse IgG as a negative control, there was 
no immunoreactivity except in foci of necrotic debris. 
Scoring of AP immunohistochemistry. The cellular distribution and intensity of AP-
immunoreactivity was assessed and characterized by light microscopy. Distribution of 
staining was scored on a subjective scale whereby 0 = no anionic peptide 
immunoreactivity (AP-IR); 1 = <10% of cells in a 40X field (of epithelial cells) had AP-
IR; 2 = 10-30% of cells in a 40X field had AP-IR; 3 = 30-60% of cells in a 40X field had 
AP-IR, and 4= 60-90% of cells in a 40X field had AP-IR. Intensity of AP-IR in epithelial 
cells was also scored on a subjective scale whereby 0 = no AP-IR, 1 = nuclear staining 
93 
only, 2 = multifocal, mild cytoplasmic and diffuse nuclear staining, 3 = diffuse, light red 
cytoplasmic AP-IR, with or without nuclear staining, and 4 = diffuse, bright red 
cytoplasmic AP-IR. 
Statistical analysis. The results of the subjectively scored slides were analyzed by the 
Kxuskal-Wallis test. All calculation were done with SAS statistical software (SAS 
Institute, Gary, NC). Results were classified as significant when P < 0.05. 
Results 
Gross lesions. Animals that received the bacterial inoculum and were killed at 
postinoculation day 1 showed severe lesions of hemorrhage and consolidation In the right 
lung.''' In two animals, the pleural surface covering the affected areas had a coarse 
covering of fibrin strands. 
Many fibrous adhesions were present between parietal and visceral pleura of sheep 
euthanatized on postinoculation day 15. There were muUifocal areas of consolidation in 
the cranial lung lobes. One animal also had fibrous adhesions between pleura and 
pericardium. Sections of the affected lungs contained abscesses with extensive areas of 
necrosis in two animals. In lungs firom the postinoculation day 45 group, the lesions were 
more variable, including multifocal consolidation, fibrous pleural adhesions, and 
increased firmness of the lungs. Macroscopic lesions in controls were practically absent 
except in two cases in which small, discrete areas of grayish discoloration were present at 
the cranial part of the cranial lobe. The non-inoculated (left) lungs lacked grossly 
detectable lesions in all of the animals. 
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Microscopic lesions. The lungs of animals killed postinoculation day I that received 
bacterial broth had extensive areas of edema, hemorrhage, and necrosis typical of M 
haemolytica pneumonia.'"' Bronchioles and alveolar spaces were filled with neutrophils, 
seroproteinaceous fluid, and cell debris. Fibrin thrombi were present in some small blood 
vessels and interlobular lymphatics. One animal in this group had mild hyperplasia of 
peribronchiolar lymphoid tissue in focal areas. 
In the postinoculation day 15 group, histologic lesions of lung lobes that had received 
bacterial inoculation were characterized by large foci of caseonecrotic and 
pyogranulomatous bronchiectasis surrounded by lobular, suppurative bronchopneumonia, 
fibrous connective tissue in alveolar septa, and marked proliferation of large, cuboidal 
epithelial cells in bronchioles and alveoli and infiltrates of lymphocytes and plasma cells 
in large bronchi. There was an underlying pattern of mild interstitial pneumonia and 
peribronchiolar lymphoid hyperplasia in all sections of lung examined. The lesions were 
less severe and characterized by alveolar and bronchiolar epithelialization. 
Animals euthanatized on postinoculation day 45 that received the bacterial inoculum 
exhibited a varying degrees of chronic changes, including alveolar and bronchiolar 
fibrosis and proliferation of bronchiolar epithelium, accompanied by a marked infiltration 
of lymphocytes and plasma cells. In the lung of one animal in this group, small airways 
were surrounded by fibrous connective tissue that sometimes encroached on tortuous 
bronchioles or even formed organized masses inside lumen (bronchiolitis fibrosa 
obliterans). Alveolar and bronchiolar lumina contained occasional clusters of neutrophils 
and cell debris. A second animal in this group had small, multifocal aggregates of 
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lymphocytes and macrophages around bronchioles with mild to moderate bronchiolar 
hyperplasia. The third animal in this group lacked foci of bronchopneumonia, although 
foci of peribronchiolar lymphoid hyperplasia were present. 
Control animals lacked lung lesions. However, few animals (three) had mild 
hyperplasia of peribronchiolar lymphoid tissue with no other significant changes. 
Anionic Peptide (AP) Immunoreactivity. A? immunoreactivity in lambs on 
postinoculation day I was similar to that described previously in acute pneumonia of 
cattle® and sheep.^ In lambs of the postinoculation day 15 group, diffuse AP-
immunoreactivity was present in hyperplastic bronchiolar epithelial cells associated with 
foci of bronchopneumonia. There was also AP-immunoreactivity in individual bronchial 
and bronchiolar epithelial cells adjacent to foci of peribronchial lymphoid hyperplasia. In 
remaining areas of lung, AP-immunoreactivity was similar to control sections 
(contralateral and saline-inoculated lung). AP-immunoreactivity was present in cuboidal 
bronchiolar epithelium in foci of early fibrosing bronchiolar obliterans (Fig. 1 A), and 
prominent AP-immunoreactivity was present in hyperplastic cells of bronchioles and 
alveoli (Fig. IB). In lungs of lambs in the postinoculation day 45 group, AP-
immunoreactivity was intense in the cytoplasm of bronchiolar epithelial cells in foci of 
bronchiolitis fibrosa obliterans, as well as in cuboidal to colunmar epithelial cells 
throughout the foci of lobular bronchopneumonia (Fig. IC). The intensity of staining in 
hyperplastic bronchiolar epithelial cells was greater in the chronic (45 days) than the 
subacute pneumonia group (15 days) (Table 1). In sections of the contralateral lung lobes 
from infected animals, there were no foci of epithelial hyperplasia, other than multifocal 
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epithelial hyperplasia adjacent to foci of lymphoid hyperplasia. AP-immunoreactivity 
was present in bronchiolar epithelium adjacent to lymphoid hyperplasia, but not in any 
other foci (Table 2). In both the subacute and chronic pneumonia lesions, there was no 
immunoreactivity in hyperplastic bronchiolar epithelium when the tissues were incubated 
with non-specific mouse IgG (Fig. 2A). AP-immunoreactivity was mild in bronchioles of 
the lung lobes contralateral to inoculated lobes (Fig. 2B). There was mild, diffuse AP-
immunoreactivity in the bronchial and bronchiolar epithelial cells of lambs inoculated 
with saline (Table 3). Although there were distinct visual differences in the intensity of 
AP-immunoreactivity between the acute lesions vs. the subacute and chronic lesions, 
there were no statistical differences in the subjective scores as determined by the 
ICruskal-Wallis test. 
Discussion 
In this model of Mannheimia (Pasteurella) haemolytica pneumonia in ruminants, 
typical lesions are located principally at the site of inoculum deposition.'' ^  Moreover, the 
procedure results in minimal compromise of the contralateral, non-inoculated lung. This 
characteristic permits bacteria-inoculated animals to develop a focal lesion of pneumonic 
pasteurellosis that may evolve similarly to that seen in natural infections. The time points 
for euthanasia were chosen as representative of the acute, sub-acute, and chronic stages 
of the pneumonic lesion. Lopez described bronchiolitis obliterans, bronchiectasis, 
pulmonary sequestra and abscesses, pulmonary fibrosis, and chronic pleuritis with fibrous 
pleural adhesions in animals surviving an acute episode of pneumonic pasteurellosis."' In 
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the present study, all of these changes were found in animals killed at postinoculation 
days 15 and 45 after bacterial inoculation. We suspect that the lesions of mild 
hyperplasia of peribronchiolar lymphoid tissue present in control lambs may have been 
secondary to Mycoplasma ovipneumoniae. 
In this study, the production of anionic peptide (AP) in lung tissue of lambs with acute, 
subacute, and chronic pneumonia due to infection with M haemolytica were compared. 
By immunohistochemistry, an unexpected and striking increase in production of AP was 
detected in lesions of subacute to chronic bacterial pneumonia. The increased AP 
production was specifically located in the cytoplasm of hyperplastic bronchiolar 
epithelium, a lesion present only in the subacute and chronic groups in this study. 
There was mild bronchial and bronchiolar AP-immunoreactivity in normal control 
animals, as well as in lung sections from the contralateral, non-inoculated lung lobes of 
infected animals of all three groups. This AP-inmiunoreactivity was similar to previous 
studies in sheep, cattle, and humans. In the post-inoculation fifteen and forty-five day 
groups, there was marked AP-IR in hyperplastic bronchiolar and alveolar type II 
epithelial cells. This suggests that while AP production is not up regulated in response to 
acute inflammation, production of AP (or its parent zymogen compound^' may be an 
essential part of lesion resolution and epithelial hyperplasia. Furthermore, AP production 
appears to be maximal in immature cells. This supports the finding of increased AP-
immunoreactivity in fetal respiratory tissues relative to tissues from neonatal calves and 
adult cattle.^ The mechanisms and relevance of the apparent maturity-dependent 
production and release of AP from epithelial cells is unknown. Identification and 
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characterization of the parent zymogen compound is necessary to understand this and 
other aspects of AP. 
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Table 1. Distribution and intensity of immunoreactivity for Anionic Peptide in 
lungs of sheep with acute, subacute, and chronic infections with Mannheimia 
(Pasteurelia) haemoiytica. Distribution and intensity of AP-immunoreactivity were 
scored whereby 0 = no anionic peptide immunoreactivity (AP-IR); I = <10% of cells in a 
40X field (of epithelial cells) had AP-IR; 2 = 10-30% of cells in a 40X field had AP-IR; 3 
= 30-60% of cells in a 40X field had AP-IR, and 4= 60-90% of cells in a 40X field had 
AP-IR. Intensity of AP-IR in epithelial cells was also scored on a subjective scale 
whereby 0 = no AP-IR, 1 = nuclear staining only, 2 = multifocal, mild cytoplasmic and 
diffuse nuclear staining, 3 = diffuse, light red cytoplasmic AP-IR, with or without nuclear 
staining, and 4 = diffuse, bright red cytoplasmic AP-IR. Individual scores of each animal 
within a group are presented. 
Duration Distribution of AP" Intensity of AP 
Acute'' (1 day) 2/3 2/2 
Subacute*^ (15 days) 3/3/3 3/3/3 
Chronic*^ (45 days) -/4/2'' -/4/2'' 
" Epithelium assessed for this table (I) in defined as bronchiolar epithelium in foci of 
suppurative to pyogranulomatous bronchopneumonia. 
''N = 2. 
'=N =  3.  
Lung sections firom two of these three animals lacked severe lesions of chronic 
bronchopneumonia, although intense AP-IR was present in hyperplastic bronchiolar 
epithelium adjacent to foci of peribronchiolar lymphoid hyperplasia. 
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Table 2. Distribution and intensity of immunoreactivity for Anionic Peptide in 
contralateral lung lobe (non-inoculated lobe) of sheep inoculated with Mannheimia 
(Pasteurella) haemoiytica. The subjective scoring method for this table is the same as 
described for Table I. Scores are presented for each animal within a group. 
Duration Distribution of AP Intensity of AP 
Acute® (1 day) 1/1 1/1 
Subacute'' (15 days) 1/1/1 1/1/1 
Chronic'' (45 days) l / l / l  l / l / l  
Table 3. Distribution and intensity of immunoreactivity for Anionic Peptide in lung 
lobe of sheep inoculated with pyrogen-free saline. The subjective scoring method for 
this table is the same as described for Table 1. Scores are presented for each animal 
within a group. 
Duration Distribution of AP Intensity of AP 
Acute'' (1 day) 1.5/1/1 2/1/1 
Subacute'' (15 days) 2/1/1 1/2/1 
Chronic'' (45 days) 1/1/1 1/1/1 
''N = 2. 
''N = 3. 
Facing page 
Figure 1. Increased Anionic Peptide (AP) immunoreactivity in subacute and chronic lesions of ovine pneumonic 
pasteurellosis. A) Bronchiole, lamb euthanatized postinoculation day 15 (PID 15). This focus of bronchiolitis fibrosa 
obliterans has intense AP-immunoreactivity in the cytoplasm of hyperplastic bronchiolar epithelial cells. Magnification 
= 160X. B) Hyperplastic bronchiolar epithelium, lamb, PID 15. Intense cytoplasmic AP-immunoreactivity is present 
in cuboidal epithelium. Magnification = 160X, C) Lamb, PID 45. Bronchioles are lined by cuboidal, hyperplastic 
epithelial cells with intense cytoplasmic AP-immunoreactivity. Magnification = 64X. 
Figure 2. Negative control tissues. A) Lamb PID 15, inoculated lung lobe incubated with non-specific mouse IgG. 
There is no immunoreactivity in hyperplastic bronchiolar epithelial cells. B) Bronchiole, lamb, PID 45, non-inoculated 
lung lobe (lobe contralateral to lobe that received bacterial inoculation). There is no hyperplasia of epithelial cells, and 
mild AP-immunoreactivity. 
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Anionic Peptide is Present in Bovine Lung Tissue 
In Chapter Two, we tested our hypotheses that production of Anionic Peptide (AP) 
occurred in respiratory tissues of cattle and that the distribution had similarities to sheep 
and humans. The presence of AP in neonatal bovine lungs was detected by 
inununohistochemistry and western blot analysis using the monoclonal antibody IG9-IC2. 
The distribution of AP in the non-inflamed, neonatal bovine lung is primarily in bronchial 
and bronchiolar epithelium, and is similar to what has been reported in sheep (17). The 
intensity of the immunoreactivity in non-inflamed neonatal bovine lungs is mild to 
moderate. 
Anionic Peptide Production is Not Increased in Foci of Acute Inflammation 
In Chapter Two, we tested the hypothesis that AP production in pulmonary epithelial 
cells is constitutive and is quickly consumed in foci of acute inflammation. To test this 
hypothesis, lungs of neonatal calves were inoculated with bacteria {Pseudomonas 
aeruginosa), bacterial products (P. aeruginosa lipopolysaccharide), or pyrogen-free saline 
via fiber-optic bronchoscopy. These calves were euthanatized four hours after 
inoculation, thus the lesions induced by bronchoscopic deposition of inocula were 
peracute to acute in duration. Immunoreactivity for AP was present in the same 
distribution between inflamed and non-inflamed lung tissue. Therefore, there were no 
data to support the hypothesis that AP would be increased in foci of acute inflammation. 
This is unlike other antimicrobial peptides, such as human P-defensin-2 and bovine 
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tracheal antimicrobial peptide, that are up-regulated in the presence of inflammatory 
mediators (e.g. LPS, II-1,11-8, TNF-a). AP production in the bovine lung was not 
influenced (e.g. enhanced) by acute inflammation. 
Anionic Peptide is Produced in a Greater Distribution of Fetal Respiratory 
Epithelium than in Neonatal and Adult Tissues 
Upon comparison of AP production in the lung of fetal, neonatal and adult cattle, we 
determined that AP production was widespread in the respiratory tissues of the single 
bovine fetus used in this study. Epithelium of fetal bronchi, bronchioles, alveoli, nasal 
mucosa and trachea was more intensely immunoreactive than that of both neonatal and 
adult lung tissue. This implies that AP production is maximal in immature epithelial 
cells. This finding, along with those of Chapter Two, support the idea that production of 
AP (or parent zymogen compound, 16) occurs in an early stage of cellular development 
and does not occur as a response to inflammation. Additional studies in this area could 
focus on studying an increased number of bovine fetuses, as only one was used in this 
study. Furthermore, lung tissue of ovine fetuses should be examined. Finally, the single 
fetus used in this study was a near term bovine fetus; at this point we do not know when 
production of AP begins in the developing fetus. 
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Anionic Peptide is Produced at Some but Not All Non-inflamed Mucosal Surfaces 
Having Potential Exposure to Bacteria 
AP is produced in endometrial epithelium and submucosal glands of the uterus, 
epithelium of the upper and lower respiratory tract, and epithelium of the gall bladder. 
These mucosal surfaces are all lined by pseudostratified columnar or tall columnar 
epithelium. Surfaces lined by stratified squamous epithelium, such as interfollicular 
epithelium of haired skin as well as buccal, glossal and esophageal epithelium lacked 
immunoreactivity for AP by immunohistochemistry. Transitional epithelium of the 
urinary bladder did not produce AP, nor did mucosae of the rumen, abomasum, small and 
large intestine, cecum and rectum. 
Anionic Peptide is Produced in Some Areas that are Unlikely 
to be Exposed to Bacteria 
Our hypothesis was that AP production would be highest at sites of mucosal 
interaction with environmental microbes. While AP production did not occur in some 
expected locations, such as in the gastrointestinal tract, it is produced in areas that are 
unlikely to be exposed to pathogens. For example, the inner root sheath epithelium of 
hair follicles had specific localization of AP-immunoreactivity although remaining 
epithelium (within the hair follicle, and also interfollicular epithelium) lacked 
immunoreactivity. The reason for AP production in this site was not determined. 
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Immunoreactivity for Anionic Peptide is Highest in Hyperplastic Bronchiolar 
Epithelium in Subacute and Chronic Lesions of Pneumonic Pasteurellosis 
In sheep infected with Mamheimia haemolytica, subacute and chronic lesions of 
bronchiolitis fibrosa obliterans and bronchiolar epithelial hyperplasia were the sites of 
highest immunoreactivity for AP. These hyperplastic epithelial cells of bronchioles were 
intensely immunoreactive for AP and this intensity has not been described previously. 
The finding of enhanced AP-immunoreactivity in immature (hyperplastic) epithelial cells 
has similarities with the findings of Chapter Three, in which we reported that AP-
immunoreactivity was more intense, and more widely distributed, in fetal respiratory 
epithelium compared to neonatal and adult tissues. It is not known if this pattern of 
immunoreactivity for AP is specific for pneumonic pasteurellosis, or if other pathogens, 
including viruses, would result in the same pattern. For example, this pattern of increased 
AP production may not occur in infections with viral pathogens that inhibit or reduce 
protein synthesis of the host cell. 
We are unable to determine with immunohistochemistry alone if the increased 
intensity of AP-immunoreactivity in hyperplastic bronchiolar epithelial cells is reflective 
of increased concentration of AP or of an intact precursor zymogen protein. It would 
appear that AP production occurs early in cellular maturation and does not increase in 
response to mediators that induce production of other antimicrobial peptides. The role of 
increased AP concentration in hyperplastic epithelium may be to protect immature 
epithelial cells while mucosal defenses are still developing. 
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Up-regulation of Anionic Peptide Production by Pharmaceutical Manipulation is 
Not Likely to be Biologically Efficient in Prevention of Pneumonia. 
Because AP production is maximal in hyperplastic epithelial cells of subacute and 
chronic lesions rather than in mature cells, there would be limited effectiveness of 
attempts to increase AP production in respiratory epithelial cells to prevent bacterial 
growth in healthy, mature tissues. However, there are potential exceptions, such as up-
regulation of AP in immature epithelial cells. Premature infants or animals could 
possibly benefit from increased production or earlier release of AP. In addition, 
immature hyperplastic epithelial cells in foci of subacute or chronic pneumonia could 
potentially be stimulated to produce increased amounts of AP. However, we do not yet 
know if the increase in AP-immunoreactivity in hyperplastic epithelial cells (presumably 
an increase in concentration of AP) is correlated with increased antimicrobial activity in 
the local microenvironment. 
The Vitamin A Derivative, RBG, is Not Effective in Up-regulating AP Production 
in Healthy Ovine Respiratory Epithelial Cells of Full Term Neonatal Lambs. 
RBG, a water-soluble, non-toxic derivative of vitamin A, did not cause an increase in 
cellular differentiation nor AP production when given in high doses by intratracheal and 
intranasal inoculation to neonatal lambs (Appendix A). In light of the findings of Chapter 
4, this experiment should be repeated with the inclusion of subacutely and chronically 
infected animals in order to determine if enhanced differentiation of damaged lung 
epithelial cells is associated with a further increase in AP production. 
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APPENDIX A. EFFECT OF A WATER-SOLUBLE VITAMIN A COMPOUND 
ON CELLULAR MATURATION AND PRODUCTION OF ANIONIC PEPTIDE 
IN NON-EVFLAMED RESPIRATORY TRACT OF NEONATAL SHEEP 
Introduction 
Anionic Peptide (AP) appears to be constitutively produced. Prior to our finding of 
increased AP in fetal and immature (hyperplastic) cells, it was our hypothesis that 
enhanced differentiation of epithelial cells may lead to increased AP production. We 
assessed the impact of cellular differentiation in the production of AP in non-inflamed, 
neonatal lungs of ruminants. Our method of increasing cellular differentiation was to 
instill a water-soluble, non-toxic vitamin A compound (retinoyl p-glucuronide, RBG) 
into the nasal cavity and trachea of lambs. We compared AP production of ovine tracheal 
mucosal cells that received vitamin A in vivo to mucosa that received pyrogen-free saline. 
We chose vitamin A as a inducer of AP production because retinoids have long been 
known to induce differentiation in epithelial cells of the respiratory tract (1,2,3). The 
water soluble nature of RBG allows it to be included in media used for cultured tracheal 
epithelial cells and for direct deposition onto mucosal surfaces. Since it is non-toxic, it 
allows differentiation without cellular injury. Therefore, RBG has potential as a therapy 
for immature lungs of neonatal infants and animals in resolution stages of pneumonia. 
Sheep were treated with either RBG or saline over multiple time points over a two 
week period, and euthanatized at three points in time during this interval (at 
postinoculation day 4, 7,14). Neonatal sheep were used because we expected that 
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epithelium of very young animals would be more readily responsive to retinoids than that 
of adult animals. The tissues (nasal septum, trachea, lung) were assessed for differences 
in cellular differentiation by gross and histologic examination with routine hematoxylin 
and eosin preparations. Production of AP was assessed by immunohistochemistry. We 
did not see morphologic changes or any differences in AP production in the RBG treated 
or saline treated lambs. 
Methods and Materials 
Eighteen lambs, mixed breed and gender, were purchased from the Iowa State 
University Laboratory Animal Resources unit. The animals were maintained in isolation 
rooms in accordance with the procedures approved by the American Association of 
Laboratory Animal Care. On the day after arrival (Day 1), the sheep were randomly 
divided into two groups, those that received saline inoculation (n = 9) and those that 
received RBG (n = 9). The treatments were given on days 1, 2, 3, 5, 7, and 12. Within 
both treatment groups, lambs were euthanatized 3 days, 7 days, and 14 days after the 
initial instillation of saline or RBG. This arrangement gave six groups, each one with 
three animals. Three animals died in the begiiming of the experiment, thus the actual 
treatment groups were: saline, postinoculation day (PID) 4, (n = 2), RBG, PID 4 (n =2), 
saline, PID 7 (n = 2), RBG, PID 7 (n = 2), saline, PID 14 (n = 3), RBG, PID 14 (n = 3). 
Instillation of solubilized RBG was performed by administration of the compound via 
intranasal inoculation and intratracheal inoculation. Lambs were lightly sedated for this 
procedure using 0.1ml xylazine IV, which was reversed after the procedure with 0.1 ml 
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reversal agent IM. Three mis of RBG solution were sprayed into the left nostril of treated 
lambs with a 5cc syringe. Five mis of RBG solution were introduced directly into the 
trachea using a 1.5 inch 20 gauge needle and a 10 cc syringe. This dose was chosen 
because small amounts of RBG induces differentiation in cultured ovine and human 
epithelial cells (1). 
At the designated time points, lambs were euthanatized with an intravenous overdose 
of sodium pentobarbital. Bilateral sections were collected from nasal turbinates, nasal 
septum, trachea, and two sections of lung from both the right and left cranial lung lobes; 
sections collected and marked such that right and left sides were identified. Samples 
collected for immunohistochemistry were placed in 10% neutral buffered formalin (48 
hours at room temperature). 
Tissues were processed for routine hematoxylin and eosin sections, as well as for 
immunohistochemistry using a mouse monoclonal antibody, IG9-1C2 (4), against anionic 
peptide (AP). Slides were deparaffinized and subjected to antigen retrieval (microwaved 
for 5 minutes in pH 6.0 citrate buffer, then cooled in a -20 C freezer for 15 minutes). 
Slides were washed in TNTB buffer (0.05M Tris, 0.85% NaCl, 0.05% Tween 20,1% 
BSA), then incubated with IG9-IC2 mouse anti-AP IgG, 1:1000 dilution, overnight in a 
humidified chamber at 4° C. Anti-AP IgG (IG9-IC2) was produced in CFl mice against 
the synthetic peptide H-DDDDDDD-OH conjugated to keyhole limpet hemocyanin (4). 
Slides were rinsed with TNTB the following morning and incubated for 30 minutes at 
room temperature with biotinylated goat anti-mouse IgG, 1:400 dilution (Vector, 
Burlingname, CA). Slides were rinsed in BioGenex wash buffer, then alkaline-
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phosphatase-conjugated streptavidin (BioGenex, San Ramon, CA) was applied for 30 
minutes. Slides were rinsed and then exposed to chromagen (Vector Red) for 10 to 18 
minutes, rinsed, counter-stained and coverslipped. Specificity of antibody affinity with 
tissue sections was determined by pre-incubating the primary antibody with varying 
concentrations of synthetic AP. Two types of negative controls were used. Conttol 
sections, which were not incubated with primary antibody, did not have 
immunoreactivity. When using nonspecific mouse IgG as a negative control, there was 
no immunoreactivity except in foci of necrotic debris. 
Macroscopic assessment of tissue development was performed at necropsy. Tissues 
were evaluated histologically for organization of epithelium (pseudostratified, tall 
columnar or cuboidal), number of goblet cells in three 40X fields, and cilia development 
(scant, present in multifocal areas, or diffusely abundant). In the nasal mucosa and 
trachea, the number of submucosal glands were counted in five 40X fields. Assessment 
of cellular distribution and intensity of AP-immunoreactivity was assessed and 
characterized by light microscopy. Distribution of staining was scored on a subjective 
scale whereby 0 = no anionic peptide immunoreactivity (AP-IR); 1 = <10% of cells in a 
40X field (of epithelial cells) had AP-IR; 2 = 10-30% of cells in a 40X field had AP-IR; 3 
= 30-60 of cells in a 40X had AP-IR, and 4= 60-90% of cells had AP-IR. Intensity of 
AP-IR in epithelial cells was also scored on a subjective scale whereby 0 = no AP-IR, 1 = 
nuclear staining only, 2 = multifocal, mild cytoplasmic and diffuse nuclear staining, 3 = 
multifocal, bright cytoplasmic AP-IR, with or without nuclear staining, and 4 = diffuse, 
bright cytoplasmic AP-IR. 
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Results 
On macroscopic examination, differences in tissue development between the two 
groups were not detected. Histologically, there were individual differences in cilial 
development, numbers of submucosal gland lumina, and goblet cell numbers. However, 
these differences did not correspond to whether or not the animal had received treatment 
with RBG. There was also no difference between treated and non-treated groups in AP 
production. 
Discussion 
The hypothesis of this component was that in vivo production of AP could be enhanced 
by accelerated maturity of tracheal epithelium by RBG. We chose RBG because it has 
been shown to enhances differentiation of HL-60 ceils in vitro without the toxicity of 
other retinoid derivatives (1). 
The inability of RBG to induce changes in differentiation of AP production was 
possibly due to inadequate dosage, limited duration of vitamin application, or simply that 
ovine tracheal epithelial cells of neonatal lambs is refiractive to growth properties of RBG. 
Because there were no morphologic or histopathologic changes in the lung following 
RBG, respiratory epithelium of healthy, full term lambs may be refractory to RBG 
treatment. Given the fmdings of Chapter Four, in which lambs with subacute and chronic 
lesions of bronchopneumonia due to Mannheimia haemolytica had marked intensity of 
AP-immunoreactivity in hyperplastic bronchiolar cells, it may be that the optimal site for 
enhanced AP production is in immature or hyperplastic epithelial cells. An additional 
115 
Study is proposed using RBG in Iambs infected with M haemolytica. Intensity of AP-
immunoreactivity should be assessed at multiple time points during the first two 
postinoculation weeks, to assess any difference in effectiveness of RBG induced increase 
of epithelial hyperplasia in subacute lesions. In addition, differences in AP production 
might be present between treated and non-treated animals. Time points should also be 
taken in the chronic stages of the disease (i.e. postinoculation day 45). Since RBG 
potentially enhances cell differentiation, the lack of RBG-induced changes in AP 
production supports, indirectly, the notion that AP production is maximal in immature 
cells. Further studies assessing the mechanistic basis of this finding may be useful in 
protecting neonates from infection. 
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APPENDIX B. SUMMARY OF ANTIMICROBIAL PEPTIDES IN MAMMALS 
AND POULTRY 
Antimicrobial peptides present in humans, primates, cattle, goats, sheep, pigs, mice, 
rabbits, chickens and turkeys are included in a chart on the following page. The 
references numbers listed for information in this chart are consistent with the 
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